Treatment of Cutaneous Lymphomas: an Update | Actas Dermo-Sifiliográficas

array:24 ["pii" => "S1578219012002727" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.09.016" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "575" "copyright" => "Elsevier España, S.L. and AEDV" "copyrightAnyo" => "2011" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2012;103:694-707" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3008 "formatos" => array:3 [ "EPUB" => 39 "HTML" => 2160 "PDF" => 809 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731012001081" "issn" => "00017310" "doi" => "10.1016/j.ad.2012.01.011" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "575" "copyright" => "Elsevier España, S.L. y AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2012;103:694-707" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7558 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 5002 "PDF" => 2555 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "Novedades en Dermatología" "titulo" => "Actualización terapéutica en linfomas cutáneos" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "694" "paginaFinal" => "707" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Treatment of Cutaneous Lymphomas: an Update" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R.M. Izu-Belloso, J.C. García-Ruiz" "autores" => array:2 [ 0 => array:2 [ "nombre" => "R.M." "apellidos" => "Izu-Belloso" ] 1 => array:2 [ "nombre" => "J.C." "apellidos" => "García-Ruiz" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219012002727" "doi" => "10.1016/j.adengl.2012.09.016" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002727?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012001081?idApp=UINPBA000044" "url" => "/00017310/0000010300000008/v1_201304241522/S0001731012001081/v1_201304241522/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219012002909" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.03.020" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "648" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103:708-17" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2420 "formatos" => array:3 [ "EPUB" => 48 "HTML" => 1741 "PDF" => 631 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Oral Propranolol for Treating Infantile Hemangiomas: A Case Series of 57 Patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "708" "paginaFinal" => "717" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Propranolol oral en el Tratamiento de los Hemangiomas de la Infancia: Serie de 57 pacientes" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 342 "Ancho" => 1000 "Tamanyo" => 60883 ] ] "descripcion" => array:1 [ "en" => "Patient number 26. (A) Start at two months and (B) fifth-month follow-up." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.S. Zegpi-Trueba, Á. Abarzúa-Araya, S. Silva-Valenzuela, C. Navarrete-Dechent, P. Uribe-González, C. Nicklas-Díaz" "autores" => array:6 [ 0 => array:2 [ "nombre" => "M.S." "apellidos" => "Zegpi-Trueba" ] 1 => array:2 [ "nombre" => "Á." "apellidos" => "Abarzúa-Araya" ] 2 => array:2 [ "nombre" => "S." "apellidos" => "Silva-Valenzuela" ] 3 => array:2 [ "nombre" => "C." "apellidos" => "Navarrete-Dechent" ] 4 => array:2 [ "nombre" => "P." "apellidos" => "Uribe-González" ] 5 => array:2 [ "nombre" => "C." "apellidos" => "Nicklas-Díaz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0001731012002414" "doi" => "10.1016/j.ad.2012.03.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012002414?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002909?idApp=UINPBA000044" "url" => "/15782190/0000010300000008/v1_201304241323/S1578219012002909/v1_201304241323/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219012002569" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.09.003" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "534" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2012;103:679-93" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 12598 "formatos" => array:3 [ "EPUB" => 57 "HTML" => 10814 "PDF" => 1727 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "REVIEW ARTICLE" "titulo" => "Congenital Syphilis in the 21st Century" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "679" "paginaFinal" => "693" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Sífilis congénita en el siglo xxi" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1260 "Ancho" => 2262 "Tamanyo" => 180829 ] ] "descripcion" => array:1 [ "en" => "New cases of congenital syphilis in each autonomous community in Spain." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "C. Rodríguez-Cerdeira, V.G. Silami-Lopes" "autores" => array:2 [ 0 => array:2 [ "nombre" => "C." "apellidos" => "Rodríguez-Cerdeira" ] 1 => array:2 [ "nombre" => "V.G." "apellidos" => "Silami-Lopes" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731011005278" "doi" => "10.1016/j.ad.2011.10.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731011005278?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002569?idApp=UINPBA000044" "url" => "/15782190/0000010300000008/v1_201304241323/S1578219012002569/v1_201304241323/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "Novelties in Dermatology" "titulo" => "Treatment of Cutaneous Lymphomas: an Update" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "694" "paginaFinal" => "707" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "R.M. Izu-Belloso, J.C. García-Ruiz" "autores" => array:2 [ 0 => array:4 [ "nombre" => "R.M." "apellidos" => "Izu-Belloso" "email" => array:1 [ 0 => "rizu@ya.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "¿" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J.C." "apellidos" => "García-Ruiz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital de Basurto, Bilbao, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Hematología y Hemoterapia, Hospital de Cruces, Barakaldo, Bizkaia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Coorresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Actualización terapéutica en linfomas cutáneos" ] ] "textoCompleto" => "IntroductionPrimary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoid malignancies that originate primarily in the skin.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> Most (75%) are derived from T cells (primary cutaneous T-cell lymphoma [CTCL]) while 20% to 25% are derived from B cells (primary cutaneous B-cell lymphoma [CBCL]). Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common such PCLs. It is important to differentiate PCLs from their equivalent lymph node disease, given that they show clinical and histopathologic differences and have different immunophenotypes and a different molecular biology. Most importantly, PCLs have a more indolent course in most cases and different treatment regimens are used.For a correct diagnosis and hence appropriate treatment, it is necessary to be familiar with the latest classifications such as those of the European Organisation for Research and Treatment of Cancer (EORTC)/World Health Organization (WHO)<a class="elsevierStyleCrossRef" href="#bib0005">1</a> (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>) and the WHO (2008).<a class="elsevierStyleCrossRefs" href="#bib0010">2,3</a> PCLs have a very low incidence,<a class="elsevierStyleCrossRef" href="#bib0020">4</a> and most patients survive for a long time. It is therefore difficult to assess the impact of a given treatment on outcome and there are almost no case-control studies to guide us. The levels of evidence are therefore low. Ideally, all patients with PCLs would be included in a clinical trial.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Many therapeutic options are available for the management of PCL.<a class="elsevierStyleCrossRefs" href="#bib0025">5,6</a> The choice of treatment should be based mainly on the clinical stage, but other factors should also be considered such as access to treatments, age and general health of the patient, and cost-benefit ratio. In the initial stages of the disease, no data are available to demonstrate the superiority of systemic treatment (the more aggressive option) over local treatment targeting the skin lesions. A conservative approach is therefore recommended.The treatments can be divided into 2 broad groups:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">1Treatments that target the skin and act only on the population of neoplastic cells in the skin. In this case, the adverse effects are usually less severe than those arising with systemic treatments. This type of treatment is in practice the only one recommended for first-line treatment of early phases of MF. In advanced stages, it is still an important option, forming part of combination therapies. Such treatments include:<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0010">-Topical corticosteroids</li><li class="elsevierStyleListItem" id="lsti0015">-Alkylating agents: topical nitrogen mustard (mechlorethamine) and carmustine</li><li class="elsevierStyleListItem" id="lsti0020">-Narrow-band UV-B phototherapy, psoralens+UV-A (PUVA), and other types of phototherapy</li><li class="elsevierStyleListItem" id="lsti0025">-Radiotherapy (conventional and electron beam)</li></ul></li><li class="elsevierStyleListItem" id="lsti0030">2Systemic treatments, which include biological response modifiers (such as retinoids, cytokines, immunotoxins and vaccines, monoclonal antibodies, and histone deacetylase inhibitors), chemotherapy (traditional single- or multiagent chemotherapy or polychemotherapy, new chemotherapies), and allogeneic stem cell transplantation.</li></ul>Treatments That Target the SkinTopical CorticosteroidsCorticosteroids are able to induce apoptosis in most neoplastic lymphocytes in the skin and reduce the number of Langerhans cells, thereby interfering with the stimulation of neoplastic cells. Although such treatments have been in use for years, there are few studies of their use.<a class="elsevierStyleCrossRefs" href="#bib0035">7,8</a> Zackheim et al.<a class="elsevierStyleCrossRef" href="#bib0040">8</a> reported their experience in 79 patients with MF in the form of patches or plaques. Patients received medium- and high-potency corticosteroids (class I-III), sometimes with an occlusive dressing. In patients with stage T1 disease, 63% had complete response (CR) and 31% had partial response (PR), while in patients with stage T2 disease, 25% had CR and 57% had PR. The adverse effects observed were adrenal suppression in 10 patients, skin irritation in 2, and skin atrophy with stretch marks in 1 patient. The authors concluded that the treatment is well tolerated and effective in the very incipient stages of the disease.Alkylating AgentsAlkylating agents are drugs that act on different mechanisms and functions of DNA, thereby finally inducing cell death.Topical Mechlorethamine (Nitrogen Mustard)Although the exact mechanism of action of mechlorethamine is unknown, when administered systematically, it acts as an alkylating agent with an antimitotic effect. Its topical activity, however, appears to be mediated by immune mechanisms or by interaction with Langerhans cells. The drug is usually used as an aqueous solution with a strength of 10-20mg/100mL or as a gel (10-20mg/100g petroleum jelly).<a class="elsevierStyleCrossRefs" href="#bib0045">9–15</a> An ongoing randomized, double-blind, multicenter trial is comparing the safety and efficacy of 2 preparations of nitrogen mustard (0.02% in propylene glycol and 0.02% in petroleum jelly) in patients with stage I or IIA MF refractory to topical corticosteroids.<a class="elsevierStyleCrossRef" href="#bib0080">16</a> The preliminary results have shown similar efficacy (overall response rate [ORR] of around 70%) and a good safety profile (no systemic absorption was seen) for both preparations. In clinical practice, the drug is initially applied daily until the lesions have cleared (in 3 to 6 months with the solution and 6 to 12 months with the gel). An intermittent maintenance regimen is followed thereafter. Application to the entire body surface is usually recommended, though avoiding intertriginous areas. However, the need to treat unaffected areas is not very clear. Response varies between 50% and 75% in stage T1 and 25% and 50% in stage T2. Contact dermatitis (allergic or irritant) may arise, particularly when using the aqueous solution (30% vs <5% with the gel). Urticaria and anaphylactic reactions have also been reported. Prolonged use increases the risk of nonmelanoma skin cancer, particularly if the patients have received prior PUVA or total skin electron beam therapy. In general, myelosuppression or other systemic effects do not occur. Efficacy appears to be similar for the 2 preparations (solution and gel), although prospective studies comparing the 2, other than the one described above,<a class="elsevierStyleCrossRef" href="#bib0080">16</a> have not been undertaken. In recent years, the availability of mechlorethamine in hospital pharmacies has been limited, and so it is unfortunately being used less and less despite its efficacy.CarmustineCarmustine is an alkylating agent that induces cell death through inhibition of DNA synthesis. It is used as an alcohol solution (2mg/mL) or as an ointment.<a class="elsevierStyleCrossRefs" href="#bib0085">17–20</a> It should be applied daily to the lesioned skin, and the clearance time is similar to that of mechlorethamine. Response rates vary from 86% in stage T1 to 48% in stage T2. Most patients experience erythema, sometimes followed by persistent telangiectasia, and approximately 3% to 5% develop mild leukopenia due to myelosuppression. The agent can be used as an alternative in patients who are allergic to mechlorethamine, although the availability of carmustine is also limited.PhototherapyNarrow-Band UV-B Phototherapy (311-312nm)Several studies have shown the usefulness of narrow-band UV-B phototherapy in the initial stages of MF (CR rates of around 75%, with a mean response duration of 51 months).<a class="elsevierStyleCrossRefs" href="#bib0105">21–26</a> The risk of skin cancer is increased, however, and therapy is only effective in MF with incipient lesions with little or no infiltration, given the limited penetration of the radiation. This type of therapy is considered particularly useful in those patients who do not tolerate psoralens, those with very light skin, and those with very incipient lesions.<a class="elsevierStyleCrossRef" href="#bib0135">27</a>Psoralens Plus UV (320-400nm)PUVA is the classic treatment in the early stages of lymphatic disease.<a class="elsevierStyleCrossRefs" href="#bib0100">20,29–34</a> Usually, the patient starts with 2 to 3 weekly sessions, with the interval between sessions being reduced according to response. There is no consensus about whether it is necessary to follow a maintenance regimen once CR has been achieved.<a class="elsevierStyleCrossRef" href="#bib0175">35</a> In a study of 82 patients with MF in the form of superficial plaques and/or palpable plaques, CR was obtained in 65% and PR in 30%, with a mean response duration of 43 months.<a class="elsevierStyleCrossRef" href="#bib0140">28</a> Chronic actinic damage was observed in 10% of the patients, with the appearance of carcinomas in 6 patients: 3 with basal cell carcinoma and 3 with squamous cell carcinoma. Although there are studies that show a statistically significant increase in carcinogenesis, including melanoma, we believe that this risk is more theoretical than real, at least in this group of patients. According to the most recent studies, the disease-free interval is related to a higher cumulative dose of PUVA and longer treatment times.<a class="elsevierStyleCrossRefs" href="#bib0135">27,35</a> Although late recurrences are seen, between 30% and 50% of patients in stages IA, IB, and IIA can maintain CR for periods of up to 10 years. The disease-free survival at 5 and 10 years for patients in stage IA was 56% and 30%, respectively. For those patients in stages IB/IIA, 5- and 10-year disease-free survival was 74% and 50%, respectively. However, the overall survival did not vary significantly between those with recurrences and those without.Others Types of Phototherapy<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0035">-Extracorporeal photopheresis.<a class="elsevierStyleCrossRefs" href="#bib0180">36–39</a> In a modification of PUVA, after ingestion of psoralen, circulating mononuclear cells from the patient are exposed to UV-A. The main drawback of this approach is the high cost and, in addition, efficacy is no better than other treatments. The best responses are obtained in patients with early-stage SS who have normal CD8 counts and have not received prior aggressive therapies.</li><li class="elsevierStyleListItem" id="lsti0040">-Hypericin. This new photodynamic plant derivative induces T-lymphocyte apoptosis in association with visible or UV-A light. If preliminary results are confirmed, this option could be better than the other forms of phototherapy,<a class="elsevierStyleCrossRef" href="#bib0200">40</a> as visible light does not increase the risk of skin cancer.</li><li class="elsevierStyleListItem" id="lsti0045">-Photodynamic therapy. The use of photodynamic therapy with derivatives of 5-aminolevulinic acid could be particularly appropriate in patients with few lesions or lesions on the scalp.<a class="elsevierStyleCrossRef" href="#bib0205">41</a></li><li class="elsevierStyleListItem" id="lsti0050">-Monochromatic excimer laser light. Excimer lasers at a wavelength of 308nm have also been used and are approved by the US Food and Drug Administration (FDA) for psoriasis and vitiligo. Passeron et al.<a class="elsevierStyleCrossRefs" href="#bib0210">42,43</a> have performed a clinical trial in which good responses were obtained in very incipient lesions. This approach can therefore be considered in areas that are not usually accessible with phototherapy.</li></ul>The evidence to support these approaches is, however, limited. Likewise, there is little evidence with regard to other therapeutic options.RadiotherapyConventional (Orthovoltage)Conventional radiotherapy is used for highly infiltrated plaques or localized MF tumors refractory to other treatments.<a class="elsevierStyleCrossRef" href="#bib0220">44</a> It is particularly indicated as front-line treatment of cutaneous marginal zone B-cell lymphoma and follicle center lymphoma along with excision.<a class="elsevierStyleCrossRefs" href="#bib0225">45,56</a> The recurrence rate is higher if doses less than 30Gy are used. Local radiotherapy has also been used in solitary MF lesions with impressive results.<a class="elsevierStyleCrossRef" href="#bib0235">47</a>Total Skin Electron Radiation (Electron Beam Therapy)An electron beam is the treatment of choice for patients with MF with infiltrated plaques or small generalized tumors. The most widely used voltage is 6 MeV, and therapy is applied 4 days per week for a total dose of 3600 cGy in 10 weeks.<a class="elsevierStyleCrossRef" href="#bib0240">48</a> The treatment can be repeated several times if reduced doses are used. Adverse effects include generalized erythema, edema, scaling and exudation, apparent worsening of existing lesions, total loss of skin appendages, transverse melanonychia and, less frequently, blistering. Hair loss is usually reversible if the total dose administered has not exceeded 2500 cGy. In the longer term, patients may develop edema, hyperpigmentation, telangiectasia, and persistent xerosis, while men may become sterile.<a class="elsevierStyleCrossRefs" href="#bib0240">48–50</a>The disease-free interval can be extended according to some authors by subsequent maintenance therapy, either with mustard derivatives or PUVA.<a class="elsevierStyleCrossRefs" href="#bib0240">48,49,51,52</a> The recommendations of the EORTC on total skin electron radiation in MF were published in 2002.<a class="elsevierStyleCrossRef" href="#bib0265">53</a> The procedure is not recommended for erythrodermic CTCL (T3) given the risk of severe scaling and because the CR rates are higher in the earlier stages (CR of 90% in T1 and 70% in T2 disease) than in the more advanced stages, where the effect is only palliative.It is known that CR rate depends on the stage of the disease, the dose applied, and the electron energy.<a class="elsevierStyleCrossRef" href="#bib0255">51</a> Overall, CR rates of 96% are obtained in patients with stage IA, IB, and IIA disease; of 36% in those with stage IIB disease; and of 60% or less in patients with stage III disease. CR rates are also related to total dose (32-36Gy) and electron energy (4-6 MeV).<a class="elsevierStyleCrossRefs" href="#bib0260">52,53</a>Systemic TreatmentsBiological Response ModifiersRetinoidsIsotretinoin and etretinate have been used in the treatment of MF to similar effect. Their usefulness as monotherapy is limited, as it was seen that atypical cells were still present according to the pathology study even though the lesions had apparently healed. These agents have been combined with PUVA and interferon alfa (IFN-α). When combined with PUVA, they seem to be able to reduce the UV-A dose while with IFN-α they seem to enhance the response to interferon in early but not late disease stages. However, there are no randomized studies that compare IFN-α and IFN-α in combination with retinoids.<a class="elsevierStyleCrossRef" href="#bib0270">54</a>Bexarotene is a new retinoid (more specifically a rexinoid) whose exact mechanism of action is unknown although it inhibits growth of tumor lymphocytes and also enhances apoptosis in vitro.<a class="elsevierStyleCrossRef" href="#bib0275">55</a> Bexarotene selectively activates RXR receptors (a type of nuclear receptor activated by retinoic acid), acting as a regulator of cell differentiation and proliferation. In 2002, the FDA approved the compound, both for topical use as a 1% gel (which has so far not been marketed in Spain but can be obtained as an imported medicine) and for systemic use at an optimum dose of 300mg/m2/d. Regular laboratory testing should be performed during treatment, focusing mainly on triglyceride levels and thyroid hormones. Bexarotene induces hypertriglyceridemia, which can be marked at times. Preventive treatment should therefore be given the preceding week with statins or a fenofibrate but not with gemfibrozil as this fibrate increases the levels of bexarotene in blood, probably through inhibition of cytochrome P450. Hypothyroidism is another common adverse effect that can be controlled with administration of thyroid hormone. Bexarotene can be combined with other treatments such as PUVA or IFN-α. It may also find uses in a maintenance regimen after more aggressive therapies in patients with more advanced disease. As with other retinoids, it requires contraceptive measures in view of the risk of malformations.<a class="elsevierStyleCrossRefs" href="#bib0280">56–61</a>Interferon-alfaIFN-α is used as monotherapy administered subcutaneously (although intramuscular and intralesional administration is also possible) at a dose of 3 to 20 million units per day, 3 days a week, with a good (dose-dependent) response, particularly in early-stage disease (ORR of approximately 70%) or in combination with other therapies such as PUVA (apparently the most effective combination), retinoids, or purine analogs (fludarabine) with apparent benefit (studies that compare these options with IFN-α monotherapy are lacking). Adverse effects include flu-like syndrome, gastrointestinal disorders, bone marrow suppression, and elevated transaminases. The agent can be used for years as maintenance in patients who showed a good response and are at risk of relapse, although there is a risk of developing autoimmune diseases such as diabetes mellitus, thyroiditis, or hemolytic anemia.<a class="elsevierStyleCrossRefs" href="#bib0310">62–64</a>ImmunotoxinsDenileukin diftitox (DAB389-interleukin 2 [IL-2]) is the first fusion cytotoxin approved by the FDA for the treatment of CTCL.<a class="elsevierStyleCrossRefs" href="#bib0325">65,66</a> It acts as a specific cytotoxin for cells that express the IL-2 receptor. It is obtained by expression in Escherichia coli of the product of fusion of the human IL-2 receptor genes with cytotoxic sequences of diphtheria toxin. The agent binds to the IL-2 receptor (CD25) of T lymphocytes, thereby inhibiting protein synthesis, and is administered intravenously at a dose of 9 or 18mg/kg/d in 5-day cycles every 3 weeks. It has been shown to be particularly effective in stage IIB MF (response rate, 38%). Transient flu-like syndrome is reported in 60% to 70% of the patients, a similar figure to that seen with IFN-α. Other adverse effects such as urticaria, anaphylaxis, or vascular leak syndrome have also been reported. Some patients developed anti-DAB389 or anti-IL-2 antibodies in the first cycle, but there was no correlation with either toxicity or response. Efficacy has been boosted in recent studies through the concomitant use of oral bexarotene, particularly in patients with low or nonexistent expression of the IL-2 receptor.<a class="elsevierStyleCrossRefs" href="#bib0335">67,68</a> Combination therapy enabled lower doses of the 2 treatments to be used. The agent has been used in monotherapy in CTCLs other than MF,<a class="elsevierStyleCrossRef" href="#bib0345">69</a> and in combination with radiotherapy.<a class="elsevierStyleCrossRef" href="#bib0350">70</a>Monoclonal AntibodiesAlemtuzumabAlemtuzumab is a humanized monoclonal antibody that targets the CD52 glycoprotein expressed on the surface of T and B lymphocytes, natural killer (NK) cells, and to a lesser extent on monocytes and macrophages. The mechanism of action has not been fully elucidated but involves direct complement-mediated cell lysis and also antibody-dependent cytotoxicity and apoptosis. In 2003, its usefulness was demonstrated in 22 patients with pretreated MF/SS, most of whom had advanced disease (86%≥stage III and 36% with B symptoms) and a general poor state of health. The ORR was 55% (32% CR) and the mean response duration was 12 months.<a class="elsevierStyleCrossRef" href="#bib0355">71</a> Recently, these encouraging outcomes have been reproduced.<a class="elsevierStyleCrossRef" href="#bib0360">72</a> Alemtuzumab-induced cytopenia is potentially the most serious complication reported. Although different degrees of anemia and/or thrombocytopenia may develop due to mechanisms that are not well understood, T- and B-cell lymphopenia is a generalized finding in all patients. This predisposes them to serious opportunistic infections (particularly by cytomegalovirus and Pneumocystis jirovecii).<a class="elsevierStyleCrossRef" href="#bib0365">73</a> Alemtuzumab seems especially useful in the management of pruritus associated with the erythrodermic forms (SS).<a class="elsevierStyleCrossRefs" href="#bib0370">74,75</a>ZanolimumabZanolimumab is another monoclonal antibody, which targets the CD4 receptor expressed on T lymphocytes and macrophages. It interferes with T-cell activation by impeding the interaction of CD4 with class II molecules of the major histocompatibility complex and also induces cell lysis through antibody-mediated cytotoxicity rather than by complement-mediated effects as is the case with alemtuzumab.<a class="elsevierStyleCrossRefs" href="#bib0380">76,77</a> Zanolimumab has been shown to be effective in 2 phase II multicenter studies of 47 patients with heavily pretreated persistent and refractory CTCL (38 MF and 9 SS).<a class="elsevierStyleCrossRef" href="#bib0390">78</a> The arms in which high doses of zanolimumab were administered (560mg/wk for early stages [MF, stages IB-IIA] and 980mg/wk for advanced stages [MF, stages IIB-IVB, and SS]) achieved an ORR of 56% with an impressive mean duration of response of 81 weeks (particularly in MF). Overall, zanolimumab has an acceptable safety profile with moderate adverse effects such as dermatitis, eczemas, and infections limited to the skin and upper respiratory tract despite the severe CD4 cell depletion associated with its use. No differences were observed in the incidence of infection between the 2 different dose groups. Although a more marked CD4 cell depletion was observed among patients treated at the higher dose (560-980 vs 280mg/wk), of note was that there were no statistically significant differences in CD4 cell recovery once treatment had finished. On the basis of these findings, a pivotal phase III study was started and is currently in progress.RituximabRituximab is a chimeric (human-murine) anti-C20 monoclonal antibody that is used as monotherapy or in combination with other agents mainly for the treatment of systemic non-Hodgkin B-cell lymphoma. Several studies have found it to be effective when administered intralesionally in patients with CBCL (marginal zone and follicle center cell types).<a class="elsevierStyleCrossRefs" href="#bib0225">45,46,79,80</a> It is considered particularly useful in patients with multiple lesions or those with a high risk of recurrence, as well as in areas where we wish to avoid the unsightly sequelae of surgery and/or radiotherapy. It is also used in combination with cyclophosphamide, vincristine, and prednisone with doxorubicin (CHOP) for CBCL, leg-type.Histone Deacetylase InhibitorsHistones are proteins present in abundance in cell nuclei, where they form the chromatin of eukaryotic cells along with other types of proteins and DNA. In recent years, several molecules within the pharmacologic group of histone deacetylase inhibitors have been developed, encouraged by different experimental findings that suggest that excess histone acetylation occurs in most cancers.<a class="elsevierStyleCrossRefs" href="#bib0405">81,82</a> Four histone deacetylase inhibitors have been studied in the treatment of CTCL: vorinostat, romidepsin, panobinostat, and belinostat.VorinostatVorinostat has been authorized by the FDA for the treatment of skin manifestations of patients with CTCL which persist, progress, or recur after at least 2 systemic treatments.<a class="elsevierStyleCrossRef" href="#bib0415">83</a> However, the drug has not been marketed in Europe. The indication was established after a phase II study of 74 patients with MF/SS.<a class="elsevierStyleCrossRef" href="#bib0420">84</a> Most of these patients had advanced disease stages (61 patients with ≥IIB disease and 30 patients with SS, while 22 patients had clinically abnormal lymph nodes). All patients had received intensive treatment (96% with bexarotene, 63% with IFN-α, 61% with chemotherapy, 36% with photophoresis, and 31% with denileukin diftitox). The dose was 400mg/d, administered orally, with adjustment or suspension according to toxicity or adverse effects. Overall, 29.7% achieved response. Among patients with advanced disease (IIB or worse), 29.5% achieved response. Among patients with SS, 33.3% achieved response. Vorinostat was generally well tolerated and the adverse effects observed most frequently were gastrointestinal (nausea, diarrhea) and constitutional (asthenia, anorexia, and weight loss). Cytopenias (thrombocytopenias and anemia) were also frequently reported. Neutropenia was not observed. Fewer than 15% of the patients required a reduction in vorinostat dose and 11% had serious adverse effects, which were mainly thromboembolic phenomena. QT prolongation was only observed in 3 patients.Recent studies are using these agents in combination with other therapies such as bexarotene<a class="elsevierStyleCrossRef" href="#bib0425">85</a> or IFN-α.<a class="elsevierStyleCrossRef" href="#bib0430">86</a>RomidepsinRomidepsin is a new and potent histone deacetylase inhibitor that has been used in patients with CTCL and peripheral T-cell lymphomas. Several studies have demonstrated its usefulness,<a class="elsevierStyleCrossRefs" href="#bib0435">87–90</a> with an ORR of 41% (7% with CR and 33% with PR), a median response duration of 14.9 months, and a median time to progression of 8.3 months. The most frequently observed adverse effects were nausea, asthenia, and vomiting. Adverse effects grade 3 or worse were only observed in 33% of the patients. The most frequently observed adverse effects were disease progression (6%), fever (3%), sepsis (2%), tumor lysis syndrome (2%), and hypotension (2%). Six patients died, one possibly of treatment-related causes. QT prolongation was only observed in 2% of the patients (patients with significant cardiac abnormalities and/or those in treatment with QT prolonging agents or inhibitors of cytochrome P3A4 were excluded from the study).PanobinostatThe new histone deacetylase inhibitor, panobinostat, not only produces histone acetylation but also induces p21, cell cycle arrest, apoptosis, and HSP90 (pan-histone deacetylase inhibitor) acetylation. Its usefulness and safety profile have been demonstrated recently in a phase II study performed in 40 patients with CTCL refractory to at least 2 prior treatments (mean of 5 prior treatments per patient).<a class="elsevierStyleCrossRef" href="#bib0455">91</a> Patients received 20mg/d of panobinostat orally on days 1, 3, and 5 of each week until disease progression or intolerance. The response rates were poor. In patients who had received prior treatment with bexarotene (group 1, 25 patients), PR was obtained in 3 and 4 had stable disease. Three patients had progression. Thirty patients could not be evaluated because of limited follow-up at the time of publication. The most frequently observed adverse effects were diarrhea, thrombocytopenia, fatigue, asthenia, hypertriglyceridemia, taste alterations, nausea, and pruritus (15% of all patients). No significant QT prolongations were observed.BelinostatBelinostat is another pan-histone deacetylase inhibitor that has been tested in a phase II clinical trial with 29 patients (15 with MF, 7 with SS, 5 without either MF or SS, and 2 with unclassified disease).<a class="elsevierStyleCrossRef" href="#bib0460">92</a> The participants received 1000mg/m2 in a 30-minute infusion from day 1 to 5 of each cycle, every 3 weeks. Seventeen patients achieved stable disease for longer than 127 days. There were 2 PR and 2 CR with a median response duration of 273 days. It is important to note that the time to response was very short: 16 days (range, 14-35 days) with a substantial improvement in pruritus. There were no reports of grade 4 hematologic toxicity or cases of grade 3 QT prolongation. Four grade 3 or 4 adverse effects were observed: pruritus, erythema, edema, and adynamic ileus.OthersBortezomibBortezomib is a drug indicated as first-line treatment in patients with multiple myeloma who are not candidates for hematopoietic stem cell transplantation and in patients with a relapse after prior treatment. The group at the Hematology Institute of the University of Bologna in Italy conducted a phase II study of 12 patients (10 with advanced MF and 2 with peripheral T-cell lymphomas with isolated cutaneous involvement).<a class="elsevierStyleCrossRef" href="#bib0465">93</a> They reported an ORR of 67%, including 2 CR (17%) and 6 PR (50%). One patient with MF and 1 with peripheral T-cell lymphoma achieved CR (10% and 50%, respectively). CR lasted for more than 1 year after the last study dose in the patient with MF while relapse was observed 10 months later in the patient with peripheral T-cell lymphoma. The regimen of bortezomib used was the same as for multiple myeloma: 1.3mg/m2, given intravenously on days 1, 4, 8, and 11 of each 21-day cycle up to a total of 6 cycles. The adverse effects observed most frequently were neutropenia (2 patients [17%], WHO grade 3), thrombocytopenia (2 patients [17%], WHO grade 3), and sensory neuropathy (2 patients [17%], WHO grade 3). No infections or treatment-related deaths were reported during the study. The rationale for using bortezomib is that it can act as an inhibitor of nuclear factor κB (NF-κB), which is constitutively activated in CTCL cell lines, and induce apoptosis.<a class="elsevierStyleCrossRef" href="#bib0470">94</a> NF-κB is a transcriptional factor implicated in the generation of inflammatory responses, regulation of the cell cycle, and protection against apoptosis.LenalidomideThe antitumor effects of lenalidomide are attributed to several mechanisms of action: inhibition of the production of proinflammatory mediators by monocytes (tumor necrosis factor α, IL-1, IL-6, IL-12), enhancement of IL-2 and IFN-γ production by T lymphocytes, and enhancement of the cytotoxic activity of these cytokines and NK cells. In a phase II study, lenalidomide was administered at a dose of 10 to 25mg/d for 21 days in cycles of 28 days to 25 patients with extensively pretreated CTCL (mean of 6 prior regimens).<a class="elsevierStyleCrossRef" href="#bib0475">95</a> Seven patients achieved PR after a mean of 9 cycles of treatment. The adverse effects observed most frequently were anemia, scaling, pruritus, and leg edema. In the high-dose group, intense neutropenia was observed in 2 patients while 1 patient discontinued treatment due to dysarthria.ChemotherapyChemotherapy should only be used in CTCL in advanced stages of the disease, as it is no more effective than conservative treatment in the early phases. Almost all chemotherapy agents used for systemic lymphomas have also been used in advanced CTCL: alkylating agents, methotrexate, cisplatin, etoposide, bleomycin, vinblastine, cyclophosphamide. It is not clear whether one agent is any better than another and, in general, responses are short-lasting. The most effective combination, and therefore the most widely used one, is CHOP or CHOP without doxorubicin (CVP), but randomized studies have not been undertaken that demonstrate increased survival with any of these regimens.MethotrexateMethotrexate is the first-choice treatment in CD30+ CTCL, particularly when the patient has multiple lesions (radiotherapy is the best alternative in solitary lesions).<a class="elsevierStyleCrossRef" href="#bib0480">96</a> High weekly doses are required in some cases to achieve CR, with a higher risk of adverse effects.Recently, 2 other chemotherapies (gemcitabine and pegylated liposomal doxorubicin [DOX-PEG]) have been shown to be useful in monotherapy.GemcitabineGemcitabine is a pyrimidine antimetabolite indicated for solid tumors traditionally considered resistant to conventional treatment such as lung cancer, ovarian cancer, pancreatic cancer, and urinary bladder cancer. Its effectiveness in cutaneous lymphomas has been investigated in 2 studies. The first to these was a series of 32 patients (mostly with MF).<a class="elsevierStyleCrossRef" href="#bib0485">97</a> CR was achieved by 22% (7 patients) while PR was achieved by 53% (17 patients). Unfortunately, the study used standard criteria for assessing response as if the patients had common forms of non-Hodgkin lymphoma and not specifically cutaneous lymphoma (severity-weighted assessment tool). Response was achieved by 73% of those with MF (26 patients), with 23% with CR and 50% with PR. The only patient included with SS did not respond. The median duration of CR was 10 months (range, 4-22 months). Gemcitabine was administered as an intravenous infusion at a dose of 1200 mg/m2 for 30minutes in cycles of 28 days (total of 6 cycles) on days 1, 8, and 15 of each cycle. The most frequently reported adverse effects were cytopenias. Reversible liver toxicity was the most frequently reported nonhematologic adverse effect (13 patients, 40%). No treatment-related deaths were reported. The second study was a series of 33 patients, most of whom had heavily pretreated MF (median of 5 prior regimens) (31 patients).<a class="elsevierStyleCrossRef" href="#bib0490">98</a> Two patients had anaplastic CD30+ T-cell lymphoma. Compared to the first study, a higher dose of gemcitabine was used (1000mg/m2) but the schedule of administration and number of cycles were the same. Response was assessed using variables that included the area of skin involved, size of lymph nodes, and peripheral blood cytometry. Response was achieved by 68% of the patients (2 with CR). Myelosuppression was the most frequently observed adverse effect (grade 3 in 8 of the 33 patients) and 2 characteristic uremic hemolytic syndromes were diagnosed in patients with SS. Other adverse effects were elevated transaminase liver enzymes, mucositis, lethargy, fever, hyperpigmentation, infusion-related maculopapular rash, and different types of cardiovascular events. Another more recent multicenter study reported similar outcomes to the studies already discussed, but with significantly greater toxicity.<a class="elsevierStyleCrossRef" href="#bib0495">99</a>Pegylated Liposomal DoxorubicinDOX-PEG is approved for the treatment of advanced ovarian cancer, relapsed multiple myeloma after hematopoietic stem cell transplantation, and AIDS-associated Kaposi sarcoma. The usefulness of DOX-PEG has also been demonstrated in patients with CTCL in observational and retrospective studies. Recently, a prospective, multicenter study analyzed use of this agent in 25 patients with MF and/or SS in stages ≥II refractory to at least 2 prior lines of treatment and in patients with CD30+ large-cell CTCL.<a class="elsevierStyleCrossRef" href="#bib0500">100</a> DOX-PEG was administered intravenously every 4 weeks at a dose of 40mg/m2/d for up to 8 cycles. An objective ORR of 56% was reported (14/25 patients with CR and 9/25 with PR). Response rates were high in patients with SS, with 6 of the 10 (60%) responding. One of these responses was a CR. Response rates were also high in transformed CTCL, and 50% of these responses were a CR. In general, more adverse effects were seen than in the previous studies, with 4 episodes of serious infection and some cardiac events. DOX-PEG has also been shown to have good activity in 5 CBCLs (1 with marginal zone disease and 4 diffuse large-cell lymphomas, leg-type) in an Italian phase II pilot study (dose of 20mg/m2 every 3 or 4 weeks). An impressive prolonged CR was obtained in 4 of these patients (80%).<a class="elsevierStyleCrossRef" href="#bib0505">101</a> In another study published recently, excellent outcomes were obtained with DOX-PEG in combination with bleomycin, vinblastine, and dacarbazine (CBVD regimen) in 37 patients with advanced PCL, both of T-cell origin (19 patients) and B-cell origin (18 patients).<a class="elsevierStyleCrossRef" href="#bib0510">102</a> CR rates of 88.8% and 100%, respectively, were obtained. Between 4 and 6 cycles of CBVD were administered in the group of CTCL whereas those with CBCL received between 2 and 6 cycles (with rituximab added to the chemotherapy: R-CBVD). The safety profile was good. Subsequent allogeneic hematopoietic stem cell transplantation was performed in 3 patients (2 with CTCL and 1 with CBCL).Other ChemotherapiesForodesineForodesine is a purine analog that inhibits purine nucleoside phosphorylase. Recruitment of patients with MF/SS with refractory disease in stages ≥IB to a phase II pivotal study was completed in 2010. The preliminary results of this multicenter study have been published recently.<a class="elsevierStyleCrossRef" href="#bib0515">103</a> The overall response rate was around 30%. The most frequently observed adverse effects were nausea, tiredness, edema, dyspnea, and urinary calculi.PralatrexateThe cytotoxicity induced by pralatrexate can be 10 times greater than that of methotrexate, allowing acquired tumor resistances to be overcome. The agent has been shown to be active in advanced T-cell lymphomas and it is a promising drug for maintenance therapies in CTCL.<a class="elsevierStyleCrossRefs" href="#bib0520">104,105</a>Stem Cell TransplantationAutologous stem cell transplantation can achieve high response rates but with immediate relapse (mean time to relapse, <100 days).<a class="elsevierStyleCrossRefs" href="#bib0530">106,107</a> This approach is therefore only useful in certain patients as a means to improve quality of life or as a way to buy some time before moving on to other therapies.Long-term CR has been achieved with allogeneic stem cell transplantation, although mortality is high due mainly to graft-vs-host disease.<a class="elsevierStyleCrossRefs" href="#bib0540">108,109</a> Indeed, the efficacy of the technique is linked to the appearance of this event, known as a graft-vs-lymphoma effect,<a class="elsevierStyleCrossRef" href="#bib0550">110</a> in which the donor lymphocytes attack the tumor lymphocytes of the receptor, thereby eliminating them. Currently, regimens are used that are not myeloablative but that are nevertheless cytoreductive prior to transplant, in an attempt to improve response and reduce complications. A recent study lends support to the role of this treatment for tumoral MF (stage IIB) and SS.<a class="elsevierStyleCrossRef" href="#bib0555">111</a> The survival rates are significantly higher in patients with second CR, PR, or progression with 3 or fewer lines of prior systemic therapy. Administration of this therapy should therefore not be left too late in the course of the disease. In the short term, it may be the only curative treatment available.ConclusionsCurrently, the aim in the treatment of PCL is to avoid progression to more advanced stages of the disease as, at present, there is no curative treatment available. There are no comparative studies between different systemic treatments in patients with advanced PCL, and so treatment in these patients is not at all protocolized. There is still much debate concerning the management of this disease, and so a conservative or start low go slow approach is recommended.<a class="elsevierStyleCrossRefs" href="#bib0560">112,113</a><a class="elsevierStyleCrossRefs" href="#tbl0010">Tables 2–8</a> summarize the recommendations of the EORTC consensus on treatment as well as staging.<a class="elsevierStyleCrossRefs" href="#bib0100">20,46</a> The recommendations of the EORTC for treatment of CTCL should be reviewed in the light of new emerging therapies.<a class="elsevierStyleCrossRef" href="#bib0100">20</a><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><elsevierMultimedia ident="tbl0035"></elsevierMultimedia><elsevierMultimedia ident="tbl0040"></elsevierMultimedia>Conflicts of InterestThe authors declare that they have no conflicts of interest." "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:2 [ "identificador" => "xres96458" "titulo" => "Abstract" ] 1 => array:2 [ "identificador" => "xpalclavsec83619" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres96459" "titulo" => "Resumen" ] 3 => array:2 [ "identificador" => "xpalclavsec83618" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Treatments That Target the Skin" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Topical Corticosteroids" ] 1 => array:3 [ "identificador" => "sec0020" "titulo" => "Alkylating Agents" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0025" "titulo" => "Topical Mechlorethamine (Nitrogen Mustard)" ] ] ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Carmustine" ] 3 => array:3 [ "identificador" => "sec0035" "titulo" => "Phototherapy" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Narrow-Band UV-B Phototherapy (311-312 nm)" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Psoralens Plus UV (320-400 nm)" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "Others Types of Phototherapy" ] ] ] 4 => array:3 [ "identificador" => "sec0055" "titulo" => "Radiotherapy" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0060" "titulo" => "Conventional (Orthovoltage)" ] 1 => array:2 [ "identificador" => "sec0065" "titulo" => "Total Skin Electron Radiation (Electron Beam Therapy)" ] ] ] ] ] 6 => array:3 [ "identificador" => "sec0070" "titulo" => "Systemic Treatments" "secciones" => array:2 [ 0 => array:3 [ "identificador" => "sec0075" "titulo" => "Biological Response Modifiers" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0080" "titulo" => "Retinoids" ] 1 => array:2 [ "identificador" => "sec0085" "titulo" => "Interferon-alfa" ] 2 => array:2 [ "identificador" => "sec0090" "titulo" => "Immunotoxins" ] 3 => array:3 [ "identificador" => "sec0095" "titulo" => "Monoclonal Antibodies" "secciones" => array:8 [ 0 => array:2 [ "identificador" => "sec0100" "titulo" => "Alemtuzumab" ] 1 => array:2 [ "identificador" => "sec0105" "titulo" => "Zanolimumab" ] 2 => array:2 [ "identificador" => "sec0110" "titulo" => "Rituximab" ] 3 => array:2 [ "identificador" => "sec0115" "titulo" => "Histone Deacetylase Inhibitors" ] 4 => array:2 [ "identificador" => "sec0120" "titulo" => "Vorinostat" ] 5 => array:2 [ "identificador" => "sec0125" "titulo" => "Romidepsin" ] 6 => array:2 [ "identificador" => "sec0130" "titulo" => "Panobinostat" ] 7 => array:2 [ "identificador" => "sec0135" "titulo" => "Belinostat" ] ] ] 4 => array:3 [ "identificador" => "sec0140" "titulo" => "Others" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0145" "titulo" => "Bortezomib" ] 1 => array:2 [ "identificador" => "sec0150" "titulo" => "Lenalidomide" ] ] ] ] ] 1 => array:3 [ "identificador" => "sec0155" "titulo" => "Chemotherapy" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0160" "titulo" => "Methotrexate" ] 1 => array:2 [ "identificador" => "sec0165" "titulo" => "Gemcitabine" ] 2 => array:2 [ "identificador" => "sec0170" "titulo" => "Pegylated Liposomal Doxorubicin" ] 3 => array:3 [ "identificador" => "sec0175" "titulo" => "Other Chemotherapies" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0180" "titulo" => "Forodesine" ] 1 => array:2 [ "identificador" => "sec0185" "titulo" => "Pralatrexate" ] ] ] ] ] ] ] 7 => array:2 [ "identificador" => "sec0190" "titulo" => "Stem Cell Transplantation" ] 8 => array:2 [ "identificador" => "sec0195" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "sec0200" "titulo" => "Conflicts of Interest" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2011-08-10" "fechaAceptado" => "2012-01-29" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec83619" "palabras" => array:4 [ 0 => "Cutaneous lymphoma" 1 => "Treatment" 2 => "Update" 3 => "Review" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec83618" "palabras" => array:4 [ 0 => "Linfoma cutáneo" 1 => "Tratamiento" 2 => "Actualización" 3 => "Revisión" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Primary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoid tumors that originate primarily in the skin. Most PCLs (75%) are T-cell lymphomas and only 20% to 25% involve B cells. It is important to differentiate between cutaneous lymphomas and lymph node tumors given the differences in their molecular biology and clinical, histopathologic, and immunophenotypic features. Moreover, PCLs generally follow a more indolent course and require different treatments.Many treatment options are available for managing PLC's. The choice should be based primarily on the clinical stage of disease but must also take into consideration other factors, such as the patient's age and general health, the availability and accessibility of the treatment, and the cost-benefit ratio. It will be important to use a multidisciplinary approach, involving a team of expert dermatologists, hematologist-oncologists, and radiotherapists who are familiar with this rare disease. Recent years have seen the emergence of many new therapies, particularly for advanced stages of the disease and for patients whose tumors have proven refractory to treatment. The objective of this article is to review all the treatment options available to us." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "Los linfomas cutáneos primarios (LCP) constituyen un grupo heterogéneo de neoplasias linfoides que se originan primariamente en la piel. La mayoría (75%) son linfomas de células T y solo un 20-25% se originan a partir de los linfocitos B. Es importante diferenciar los LCP de sus equivalentes ganglionares, dado que presentan características clínicas, histopatológicas, inmunofenotípicas y de biología molecular diferentes con un pronóstico en la mayoría de los casos más indolente y tratamientos diferentes.Existen múltiples opciones terapéuticas en el manejo de los LCP. La elección del tratamiento debe basarse principalmente en el estadio clínico del paciente, pero deben considerarse también otros factores, como la accesibilidad a los tratamientos, la edad y el estado general del paciente o el coste-beneficio. Además es importante el abordaje multidisciplinar de estos pacientes, formando un equipo experto entre dermatólogos, hematooncólogos y radioterapeutas que conozcan bien esta infrecuente patología. En los últimos años asistimos a la aparición de múltiples terapias nuevas, especialmente para el tratamiento de los estadios avanzados o de pacientes refractarios a tratamientos previos. El motivo de este artículo es revisar todas las alternativas terapéuticas a nuestro alcance." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Izu-Belloso RM, García-Ruiz JC. Actualización terapéutica en linfomas cutáneos. Actas Dermosifiliogr.2012;103:694-707." ] ] "multimedia" => array:8 [ 0 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "Abbreviations: BCL, B-cell lymphoma; MF, mycosis fungoides; NK, natural killer." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cutaneous T-cell Lymphomas \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MF and variants \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Folliculotropic MF \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pagetoid reticulosis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Granulomatous slack skin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sézary syndrome \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD30+lymphoproliferative disorders \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lymphomatoid papulosis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD30+ anaplastic lymphoma \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adult T-cell leukemia/lymphoma \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Panniculitis-like T-cell lymphoma \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Extranodal NK/T-cell lymphoma, nasal-type \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Peripheral T-cell lymphoma, unspecified \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD8+ epidermotropic lymphoma \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cutaneous T-cell lymphoma \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD4+ small/medium-sized pleomorphic T-cell lymphoma \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B-Cell Cutaneous Lymphomas \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Primary cutaneous marginal zone BCL \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cutaneous follicle center BCL \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diffuse large BCL, leg-type \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cutaneous diffuse large BCL, other \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Intravascular diffuse large BCL \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neoplastic Disease With Hematologic Precursors \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD4+CD56+hematodermic neoplasm \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182525.png" ] ] ] ] "descripcion" => array:1 [ "en" => "World Health Organization/European Organisation for Research and Treatment of Cancer Classification of Primary Cutaneous Lymphomas (2005)." ] ] 1 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "In blood, Sézary cells are defined as lymphocytes with highly convoluted cerebriform nuclei. If Sézary cells cannot be used establish the tumor level B2, then 1 of the following modified criteria of the ISCL can be used along with a positive clonal rearrangement in the T-cell receptor: 1) CD4+ or C3+ expansion with a CD4/CD8 ratio of 10 or more; 2) CD4+ expansion with abnormal immunophenotype including loss of CD7 or CD26.T-cell clonality is defined by a polymerase chain reaction analysis or southern blotting of the gene that encodes the T-cell receptor.Abbreviations and definitions: Dutch, criteria established by the Dutch Cutaneous Lymphomas Group; ISCL, International Society of Cutaneous Lymphoma." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Skin</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Limited patches, papules, and/or plaques covering <10% of the body surface area. Can be staged as T1a (only patches) vs T1b (plaques±patches) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patches, papules, and/or plaques covering ≥10% of the body surface area. Can be staged as T2a (only patches) vs T2b (plaques±patches) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">One or more tumors (≥1cm in diameter) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">T4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Confluence of erythema covering ≥80% of the body surface area \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lymph nodes</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No abnormal peripheral lymph nodes. Biopsy not required \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Enlarged peripheral lymph nodes, Dutch gr 1 or NCI LN0,2 histology \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N1a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N1b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Positive clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Enlarged peripheral lymph nodes, Dutch gr 2 or NCI LN3 histology \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N2a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N2b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Positive clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Enlarged peripheral lymph nodes, Dutch gr 3-4, or NCI LN4 positive or negative clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nx \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Enlarged peripheral lymph nodes, without histologic confirmation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Visceral</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No visceral involvement \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">M1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Visceral involvement (histologic confirmation needed and the affected organ should be specified) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hematologic</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Absence of significant hematologic involvement ≤5% atypical lymphocytes (Sézary cells) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B0a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B0b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Positive clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Low hematologic involvement: >5% peripheral lymphocytes are atypical (Sézary cells) but do not meet the criterion for B2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B1a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B1b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Positive clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Extensive hematologic involvement: ≥1000/mm3 Sézary cells with positive clonality \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182521.png" ] ] ] ] "descripcion" => array:1 [ "en" => "TNMB Staging for Mycosis Fungoides/Sézary Syndrome." ] ] 2 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">T \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">N \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">B \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0,1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0,1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1-2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0,1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IIB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0,1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0,1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IIIA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IIIB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IVA1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1-4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IVA2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1-4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IVB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1-4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0-2 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182523.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Clinical Staging and Classification of Mycosis Fungoides and Sézary Syndrome." ] ] 3 => array:7 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TT1: solitary skin lesionT1a: solitary lesion<5cm diameterT1b: solitary lesion>5cm diameterT2: multiple skin lesions in 1 body region or 2 contiguous regionsT2a: all disease encompassed in 1 body region<15cm diameterT2b: all disease encompassed in 1 body region >15cm and <30cm in diameterT2c: all disease encompassed in 1 body region >30cm diameterT3: generalized cutaneous involvementT3a: multiple lesions affecting 2 noncontiguous body regionsT3b: multiple lesions affecting more than 3 body regions \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NN0: no clinical or pathologic lymph node involvementN1: involvement of 1 peripheral lymph node region that drains a region of skin involvementN2: involvement of 2 or more peripheral lymph node regions or a lymph node region that does not drain a region of skin involvementN3: involvement of central lymph nodes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MM0: no evidence of extracutaneous non-lymph-node diseaseM1: extracutaneous non-lymph-node disease \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182520.png" ] ] ] ] "descripcion" => array:1 [ "en" => "TNM Classification for Lymphomas Other Than Mycosis Fungoides/Sézary Syndrome." ] ] 4 => array:7 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "Abbreviations: ECP, extracorporeal photophoresis; IFN-α: interferon alfa; MTX, methotrexate; PUVA, psoralen + UV-A; TSEB, total skin electron beam." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">MF IA-IIA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">MF IIB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">MF III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">MF IVA-IVB \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">First-line \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PUVAUV-B (patch lesions)Topical CorticosteroidsLocal radiotherapyTSEB (< 3 treatments)CarmustineNitrogen mustard \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IFN-α+PUVATSEB, radiotherapyIFN-α+retinoidsBexarotene+PUVA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IFN-α+PUVAIFN-αMTXTSEB, radiotherapyCarmustineNitrogen mustardECBPUVA+retinoid \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ChemotherapyTSEB, radiotherapyOral bexaroteneDenileukin diftitoxIFN-αAlemtuzumabLow-dose MTX \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Second-line \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral bexaroteneIFN-αIFN-α+retinoidsDenileukin diftitoxLow-dose MTXIFN-α+PUVARetinoid+PUVABexarotene+PUVA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral bexaroteneChemotherapyDenileukin diftitox \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral bexaroteneChemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inclusion in clinical trials \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182522.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Recommendations of the European Organisation for Treatment and Research of Cancer on the Treatment of Mycosis Fungoides (MF)." ] ] 5 => array:7 [ "identificador" => "tbl0030" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "Abbreviations: IFN-α, interferon alfa; MTX, methotrexate." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">First-line \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Extracorporeal photophoresis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IFN-α \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Denileukin diftitox \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chlorambucil+prednisone \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Second-line \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral bexarotene \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Alemtuzumab \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MTX \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182519.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Recommendations of the European Organisation for Treatment and Research of Cancer on the Treatment of Sézary Syndrome." ] ] 6 => array:7 [ "identificador" => "tbl0035" "etiqueta" => "Table 7" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "Abbreviations: CHOP, cyclophosphamide, vincristine, prednisone, and doxorubicin; CVP, cyclophosphamide, vincristine, and prednisone; IFN-α, interferon alfa; IL, intralesional; IV, intravenous; MZ, mantle-zone." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Type of CBCL/Extension \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">First-Line Treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Alternative Treatment \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Solitary/localized MZ CBCL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Local radiotherapyExcisionAntibiotics<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IFN-α ILRituximab ILCorticosteroides IL \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Multifocal MZ CBCL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Watchful waitingLocal radiotherapyChlorambucil<a class="elsevierStyleCrossRef" href="#tblfn0010">b</a>Rituximab IVAntibiotics<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IFN-α ILRituximab ILCorticosteroides IL ortopical \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Solitary/localized FC CBCL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Local radiotherapyExcision \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IFN-α ILRituximab IL \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Multifocal FC CBCL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Watchful waitingLocal radiotherapyRituximab IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chemotherapy(R-CVP/CHOP) inexceptional casesor extracutaneous diseases \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Solitary/localized CBCL, leg-type \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">R-CHOP+radiotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Local radiotherapyRituximab IV \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Multifocal CBCL, leg-type \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">R-CHOP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rituximab IV \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182524.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "In the event of evidence of Borrelia burgdorferi infection." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "Other appropriate single-agent or combined chemotherapies for low-grade B-cell lymphomas." ] ] ] "descripcion" => array:1 [ "en" => "Recommendations of the European Organisation for Research and Treatment of Cancer on the Treatment of Cutaneous B-Cell Lymphoma (CBCL)." ] ] 7 => array:7 [ "identificador" => "tbl0040" "etiqueta" => "Table 8" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "Abbreviations: BCNU, carmustine; CHOP, cyclophosphamide, vincristine, prednisone, and doxorubicin; HDAC, histone deacetylase inhibitors; IFN-α, interferon alfa; MTX, methotrexate; NH2, nitrogen mustard; PUVA, psoralen + UV-A." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">First-Line \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Second-Line \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lymphomatoid papulosis</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Solitary lesion or limited number of lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No treatment (watchful waiting)Topical corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Generalized lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MTXNH2, BCNU \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PUVAIFN-αBexarotene \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD30+anaplastic large cell lymphoma</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Solitary lesion \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ExcisionRadiotherapyMTX \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IFN-α \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Multiple lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MTXRadiotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IFN-αBexaroteneDoxorubicin, CHOP, HDACDenileukin diftitox \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182518.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Treatment of CD30+ Cutaneous T-Cell Lymphoma (CTCL)." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:113 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "WHO-EORTC classification for cutaneous lymphomas" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2004-09-3502" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2005" "volumen" => "105" "paginaInicial" => "3768" "paginaFinal" => "3785" "link" => array:1 [ …1] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "WHO classification of tumours of haematopoietic and lymphoid tissues" "serieFecha" => "2008" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The 2008 WHO classification of lymphomas: implications for clinical practice and translational research" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Hematology Am Soc Hematol Educ Program" "fecha" => "2009" "paginaInicial" => "523" "paginaFinal" => "531" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2008-10-184168" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2009" "volumen" => "113" "paginaInicial" => "5064" "paginaFinal" => "5073" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Natl Compr Canc Netw" "fecha" => "2008" "volumen" => "6" "paginaInicial" => "436" "paginaFinal" => "442" "link" => array:1 [ …1] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on treatment of cutaneous T-cell lymphoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/CCO.0b013e3283253190" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Oncol" "fecha" => "2009" "volumen" => "21" "paginaInicial" => "131" "paginaFinal" => "137" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of mycosis fungoides with various strengths of fluocinolone acetonide cream" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1968" "volumen" => "97" "paginaInicial" => "165" "paginaFinal" => "172" "link" => array:1 [ …1] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical corticosteroids for mycosis fungoides. Experience in 79 patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1998" "volumen" => "134" "paginaInicial" => "949" "paginaFinal" => "954" "link" => array:1 [ …1] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Responses of mycosis fungoides to intensive external treatment with nitrogen mustard" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1970" "volumen" => "102" "paginaInicial" => "507" "paginaFinal" => "514" "link" => array:1 [ …1] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ointment-based mechlorethamine treatment for mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "1983" "volumen" => "52" "paginaInicial" => "2214" "paginaFinal" => "2219" "link" => array:1 [ …1] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical mechlorethamine chemotherapy. Considerations on its use in mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "1984" "volumen" => "23" "paginaInicial" => "180" "paginaFinal" => "186" "link" => array:1 [ …1] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mycosis fungoides: management with topical nitrogen mustard" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.1987.5.11.1796" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1987" "volumen" => "5" "paginaInicial" => "1796" "paginaFinal" => "1803" "link" => array:1 [ …1] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical mechlorethamine therapy for early stage mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1988" "volumen" => "19" "paginaInicial" => "684" "paginaFinal" => "691" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term effiﬁcacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1989" "volumen" => "20" "paginaInicial" => "416" "paginaFinal" => "428" "link" => array:1 [ …1] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2003" "volumen" => "139" "paginaInicial" => "165" "paginaFinal" => "173" "link" => array:1 [ …1] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized, pivotal trial to evaluate the safety and efficacy of 0. 02% Nitrogen Mustard formulations in patients with stage I or IIA mycosis fungoides (abstract)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "World Congress of Cutaneous Lymphoma Meeting, Chicago, IL" "serieFecha" => "September 2010" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1990" "volumen" => "22" "paginaInicial" => "802" "paginaFinal" => "810" "link" => array:1 [ …1] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical carmustine (BCNU) for patch/plaque mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Semin Dermatol" "fecha" => "1994" "volumen" => "13" "paginaInicial" => "202" "paginaFinal" => "206" "link" => array:1 [ …1] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical carmustine (BCNU) in the treatment of mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Dermatol Ther" "fecha" => "2003" "volumen" => "16" "paginaInicial" => "299" "paginaFinal" => "302" "link" => array:1 [ …1] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2006.01.025" "Revista" => array:6 [ "tituloSerie" => "Eur J Cancer" "fecha" => "2006" "volumen" => "42" "paginaInicial" => "1014" "paginaFinal" => "1030" "link" => array:1 [ …1] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fototerapia UVB en la micosis fungoide" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2000" "volumen" => "91" "paginaInicial" => "98" "paginaFinal" => "100" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Narrowband UVB phototherapy for early-stage mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2002" "volumen" => "47" "paginaInicial" => "191" "paginaFinal" => "197" "link" => array:1 [ …1] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/mjd.2003.80" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2003" "volumen" => "48" "paginaInicial" => "215" "paginaFinal" => "219" "link" => array:1 [ …1] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2006.01635.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2006" "volumen" => "20" "paginaInicial" => "804" "paginaFinal" => "809" "link" => array:1 [ …1] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamiento con UVB de banda estrecha de los estadios iniciales de la micosis fungoide. Estudio de 23 pacientes" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2007" "volumen" => "98" "paginaInicial" => "259" "paginaFinal" => "264" "link" => array:1 [ …1] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of early stages of mycosis fungoides with narrow- band ultraviolet B. A clinical, histological and molecular evaluation of results" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Br J Dermatology" "fecha" => "2009" "volumen" => "218" "paginaInicial" => "1" "paginaFinal" => "6" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1996" "volumen" => "35" "paginaInicial" => "935" "paginaFinal" => "945" "link" => array:1 [ …1] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1995" "volumen" => "33" "paginaInicial" => "234" "paginaFinal" => "242" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photochemotherapy (PUVA) in the pretumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "1981" "volumen" => "61" "paginaInicial" => "47" "paginaFinal" => "51" "link" => array:1 [ …1] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photochemotherapie bei mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Hautarzt" "fecha" => "1978" "volumen" => "29" "paginaInicial" => "191" "paginaFinal" => "197" "link" => array:1 [ …1] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta DermVenereol" "fecha" => "1996" "volumen" => "76" "paginaInicial" => "475" "paginaFinal" => "478" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PUVA treatment of erythrodermic and plaque type mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1981" "volumen" => "4" "paginaInicial" => "423" "paginaFinal" => "429" "link" => array:1 [ …1] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1985" "volumen" => "13" "paginaInicial" => "613" "paginaFinal" => "622" "link" => array:1 [ …1] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photochemotherapy for mycosis fungoides: long-term follow-up study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer Treat Rep" "fecha" => "1979" "volumen" => "63" "paginaInicial" => "669" "paginaFinal" => "673" "link" => array:1 [ …1] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phototherapy for cutaneous T-cell lymphoma: online survey and literature review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2008.08.043" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2009" "volumen" => "60" "paginaInicial" => "39" "paginaFinal" => "50" "link" => array:1 [ …1] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UVA monotherapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.141.3.305" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2005" "volumen" => "141" "paginaInicial" => "305" "paginaFinal" => "311" "link" => array:1 [ …1] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2003" "volumen" => "149" "paginaInicial" => "1095" "paginaFinal" => "1107" "link" => array:1 [ …1] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "UK consensus statement on the use of extracorporeal photophoresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2007.08415.x" "Revista" => array:7 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "158" "paginaInicial" => "659" "paginaFinal" => "678" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Extracorporeal photopheresis in dermatology" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2009" "volumen" => "100" "paginaInicial" => "459" "paginaFinal" => "471" "link" => array:1 [ …1] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2010.02.039" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2010" "volumen" => "63" "paginaInicial" => "984" "paginaFinal" => "990" "link" => array:1 [ …1] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides: a report of two cases and review of the literature" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2008.03177.x" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "410" "paginaFinal" => "413" "link" => array:1 [ …1] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of the 308-nm excimer laser in the treatment of mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.140.10.1291" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2004" "volumen" => "140" "paginaInicial" => "1291" "paginaFinal" => "1293" "link" => array:1 [ …1] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of mycosis fungoides by 308nm excimer laser: a clinical and histological study in 10 patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Dermatol Venereol" "fecha" => "2007" "volumen" => "134" "paginaInicial" => "225" "paginaFinal" => "231" "link" => array:1 [ …1] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiation therapy in the management of cutaneous T-cell lymphomas" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer Treat Rep" "fecha" => "1979" "volumen" => "63" "paginaInicial" => "625" "paginaFinal" => "632" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnóstico y tratamiento de los linfomas cutáneos primarios de células B" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2004" "volumen" => "95" "paginaInicial" => "537" "paginaFinal" => "547" ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2008-04-152850" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2008" "volumen" => "112" "paginaInicial" => "1600" "paginaFinal" => "1609" "link" => array:1 [ …1] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiotherapy for unilesional mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int J Radiot Oncol Biol Phys" "fecha" => "1998" "volumen" => "42" "paginaInicial" => "361" "paginaFinal" => "364" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Electron-beam therapy for mycosis fungoides: the Stanford University experience" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer Treat Rep" "fecha" => "1979" "volumen" => "63" "paginaInicial" => "691" "paginaFinal" => "700" "link" => array:1 [ …1] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The management of mycosis fungoides at Stanford-standard and innovative treatment programmes" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Leukemia" "fecha" => "1991" "volumen" => "5" "paginaInicial" => "46" "paginaFinal" => "48" "link" => array:1 [ …1] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "1994" "volumen" => "28" "paginaInicial" => "839" "paginaFinal" => "845" "link" => array:1 [ …1] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Electron beam treatment for cutaneous T-cell lymphoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Hematol Oncol Clin North Am" "fecha" => "1995" "volumen" => "9" "paginaInicial" => "1057" "paginaFinal" => "1076" "link" => array:1 [ …1] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "1999" "volumen" => "43" "paginaInicial" => "951" "paginaFinal" => "958" "link" => array:1 [ …1] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2002" "volumen" => "47" "paginaInicial" => "364" "paginaFinal" => "370" "link" => array:1 [ …1] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Emerging new therapies for cutaneous T-cell lymphoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Dermatol Clin" "fecha" => "2000" "volumen" => "18" "paginaInicial" => "147" "paginaFinal" => "156" "link" => array:1 [ …1] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Cancer Res" "fecha" => "2002" "volumen" => "8" "paginaInicial" => "1234" "paginaFinal" => "1240" "link" => array:1 [ …1] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0280" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.2001.19.9.2456" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2001" "volumen" => "19" "paginaInicial" => "2456" "paginaFinal" => "2471" "link" => array:1 [ …1] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0285" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Optimizing bexarotene therapy for cutaneous T-cell lymphoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2002" "volumen" => "47" "paginaInicial" => "672" "paginaFinal" => "684" "link" => array:1 [ …1] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0290" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bexarotene: a clinical review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/14737140.4.2.180" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Anticancer Ther" "fecha" => "2004" "volumen" => "4" "paginaInicial" => "180" "paginaFinal" => "188" "link" => array:1 [ …1] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0295" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamiento de linfomas de células T con bexaroteno" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermatosifiliogr" "fecha" => "2005" "volumen" => "96" "paginaInicial" => "669" "paginaFinal" => "673" ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0300" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma:an expert opinion" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2006.07329.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2006" "volumen" => "155" "paginaInicial" => "261" "paginaFinal" => "266" "link" => array:1 [ …1] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0305" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bexarotene therapy for mycosis fungoides and Sézary syndrome" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Br J Dematol" "fecha" => "2009" "volumen" => "160" "paginaInicial" => "1299" "paginaFinal" => "1307" ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0310" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interferon in the treatment of cutaneous T-cell lymphoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Dermatol Ther" "fecha" => "2003" "volumen" => "16" "paginaInicial" => "311" "paginaFinal" => "321" "link" => array:1 [ …1] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0315" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitetrin versus interferon -2a plus PUVA in patients with cuteneous T-cell lymphoma satges I and II" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "1998" "volumen" => "92" "paginaInicial" => "3578" "paginaFinal" => "3581" "link" => array:1 [ …1] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0320" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnóstico y tratamiento de los linfomas cutáneos de células T primarios" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2004" "volumen" => "95" "paginaInicial" => "473" "paginaFinal" => "490" ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0325" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pivotal phase III trial of two doses levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.2001.19.2.376" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2001" "volumen" => "19" "paginaInicial" => "376" "paginaFinal" => "388" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0330" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical experience with denileukin diftitox (ONTAK)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.seminoncol.2010.11.002" "Revista" => array:6 [ "tituloSerie" => "Semin Oncol" "fecha" => "2006" "volumen" => "33 (Suppl 3)" …3 ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0335" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Optimizing denileukin diftitox (Ontak) therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2217/14796694.4.4.457" "Revista" => array:6 [ …6] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0340" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novel therapies for cutaneous T-cell lymphomas" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0345" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0350" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin-diftitox" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0355" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2002-09-2802" "Revista" => array:6 [ …6] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0360" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/10428190903216770" "Revista" => array:6 [ …6] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0365" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2007-03-080010" "Revista" => array:6 [ …6] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0370" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Alemtuzumab in Sézary syndrome: efficient but not innocent" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1684/ejd.2007.0269" "Revista" => array:6 [ …6] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0375" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low-dose alemtuzumab is uniquely effective in refractory leukemic cutaneous T cell lymphoma (L-CTCL). Abstrat 3748" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ …3] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0380" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/0008-5472.CAN-07-1148" "Revista" => array:6 [ …6] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib0385" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novel human antibody therapeutics: The age of the Umabs" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/biot.200800110" "Revista" => array:6 [ …6] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib0390" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2006-12-062877" "Revista" => array:6 [ …6] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib0395" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intralesional therapy with anti-CD20 monoclonal antibody, rituximab in primary cutaneous B-lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib0400" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2006.07523.x" "Revista" => array:7 [ …7] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib0405" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histone deacetylase inhibitors in cancer therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2009.22.1291" "Revista" => array:6 [ …6] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib0410" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histone deacetylase inhibitors as novel anticancer therapeutics" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib0415" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/13543784.16.7.1111" "Revista" => array:7 [ …7] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib0420" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2006.10.2434" "Revista" => array:6 [ …6] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib0425" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: a phase I study. Abstrat 8572. En: 2009 ASCO Annual Meeting" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.1990.8.1.27" "Revista" => array:4 [ …4] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib0430" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2008.11.889" "Revista" => array:6 [ …6] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib0435" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinically Significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2B, international, multicenter, registration study. Abstract #263" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ …3] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib0440" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinically significant responses achieved with romidepsin in 37 patients with cutaneous T-cell lymphoma with blood involvement. Abstrat 2683" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ …3] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib0445" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2008.21.6150" "Revista" => array:6 [ …6] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib0450" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma. Abstrat 8546. En: 2009 ASCO Annual Meeting" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib0455" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory cutaneous T-cell lymphoma (CTCL). Abstrat 8555. En: 2008 ASCO Annual Meeting" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ …3] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib0460" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Abstrat 920" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ …3] ] ] ] ] ] 92 => array:3 [ "identificador" => "bib0465" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2007.11.4207" "Revista" => array:6 [ …6] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib0470" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2005.04.6789" "Revista" => array:6 [ …6] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib0475" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 95 => array:3 [ "identificador" => "bib0480" "etiqueta" => "96" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 96 => array:3 [ "identificador" => "bib0485" "etiqueta" => "97" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Phase II study of 32 patients" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncr.21449" "Revista" => array:6 [ …6] ] ] ] ] ] 97 => array:3 [ "identificador" => "bib0490" "etiqueta" => "98" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3816/CLM.2006.n.039" "Revista" => array:6 [ …6] ] ] ] ] ] 98 => array:3 [ "identificador" => "bib0495" "etiqueta" => "99" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gemcitabine treatment in cutaneous T-cell lymphoma: multicentre study of 23 cases" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2009.09230.x" "Revista" => array:7 [ …7] ] ] ] ] ] 99 => array:3 [ "identificador" => "bib0500" "etiqueta" => "100" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary Syndrome" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.144.6.727" "Revista" => array:6 [ …6] ] ] ] ] ] 100 => array:3 [ "identificador" => "bib0505" "etiqueta" => "101" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1600-0609.2008.01197.x" "Revista" => array:6 [ …6] ] ] ] ] ] 101 => array:3 [ "identificador" => "bib0510" "etiqueta" => "102" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pegylated liposomal doxorubicin, bleomycin, vinblastine and dacarbazine (CBVD) in the treatment of advanced primary cutaneous lymphomas. Abstrat 3717" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ …3] ] ] ] ] ] 102 => array:3 [ "identificador" => "bib0515" "etiqueta" => "103" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. En: 2009 ASCO Annual Meeting" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2009.21.8560" "Revista" => array:4 [ …4] ] ] ] ] ] 103 => array:3 [ "identificador" => "bib0520" "etiqueta" => "104" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pralatrexate is active in cutaneous T-cell lymphoma: results of a multi-center dose-finding trial. Abstract 919" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ …3] ] ] ] ] ] 104 => array:3 [ "identificador" => "bib0525" "etiqueta" => "105" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2008.20.8470" "Revista" => array:7 [ …7] ] ] ] ] ] 105 => array:3 [ "identificador" => "bib0530" "etiqueta" => "106" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Stem cell trasplantation in advanced cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2007.12.021" "Revista" => array:6 [ …6] ] ] ] ] ] 106 => array:3 [ "identificador" => "bib0535" "etiqueta" => "107" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trasplante autólogo de progenitores hematopoyéticos seguido de bexaroteno oral en paciente con micosis fungoide avanzada" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 107 => array:3 [ "identificador" => "bib0540" "etiqueta" => "108" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Durable clinical, cytogenetic and molecular remissions alter allogenic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2005.02.774" "Revista" => array:6 [ …6] ] ] ] ] ] 108 => array:3 [ "identificador" => "bib0545" "etiqueta" => "109" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/sj.bmt.1705968" "Revista" => array:6 [ …6] ] ] ] ] ] 109 => array:3 [ "identificador" => "bib0550" "etiqueta" => "110" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogenic stem cell transplantation" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 110 => array:3 [ "identificador" => "bib0555" "etiqueta" => "111" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2010.29.3241" "Revista" => array:6 [ …6] ] ] ] ] ] 111 => array:3 [ "identificador" => "bib0560" "etiqueta" => "112" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Controversies in the management of the cutaneous T cell lymphomas" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1529-8019.2009.01257.x" "Revista" => array:6 [ …6] ] ] ] ] ] 112 => array:3 [ "identificador" => "bib0565" "etiqueta" => "113" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2007.06.015" "Revista" => array:7 [ …7] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010300000008/v1_201304241323/S1578219012002727/v1_201304241323/en/main.assets" "Apartado" => array:4 [ "identificador" => "6170" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Novelties in Dermatology" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010300000008/v1_201304241323/S1578219012002727/v1_201304241323/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002727?idApp=UINPBA000044"]

Statistics

Novelties in Dermatology

Treatment of Cutaneous Lymphomas: an Update

Actualización terapéutica en linfomas cutáneos

R.M. Izu-Bellosoa,

Corresponding author

rizu@ya.com

Coorresponding author.

, J.C. García-Ruizb

a Servicio de Dermatología, Hospital de Basurto, Bilbao, Spain

b Servicio de Hematología y Hemoterapia, Hospital de Cruces, Barakaldo, Bizkaia, Spain

Read

7749

Times
was read the article

2659

Total PDF

5090

Total HTML

Share statistics

 array:24 [
  "pii" => "S1578219012002727"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2012.09.016"
  "estado" => "S300"
  "fechaPublicacion" => "2012-10-01"
  "aid" => "575"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46; and AEDV"
  "copyrightAnyo" => "2011"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "ssu"
  "cita" => "Actas Dermosifiliogr. 2012;103:694-707"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 3008
    "formatos" => array:3 [
      "EPUB" => 39
      "HTML" => 2160
      "PDF" => 809
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0001731012001081"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2012.01.011"
      "estado" => "S300"
      "fechaPublicacion" => "2012-10-01"
      "aid" => "575"
      "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46; y AEDV"
      "documento" => "article"
      "crossmark" => 0
      "subdocumento" => "ssu"
      "cita" => "Actas Dermosifiliogr. 2012;103:694-707"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 7558
        "formatos" => array:3 [
          "EPUB" => 1
          "HTML" => 5002
          "PDF" => 2555
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Novedades en Dermatolog&#237;a</span>"
        "titulo" => "Actualizaci&#243;n terap&#233;utica en linfomas cut&#225;neos"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "694"
            "paginaFinal" => "707"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Treatment of Cutaneous Lymphomas&#58; an Update"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "R&#46;M&#46; Izu-Belloso, J&#46;C&#46; Garc&#237;a-Ruiz"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "R&#46;M&#46;"
                "apellidos" => "Izu-Belloso"
              ]
              1 => array:2 [
                "nombre" => "J&#46;C&#46;"
                "apellidos" => "Garc&#237;a-Ruiz"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219012002727"
          "doi" => "10.1016/j.adengl.2012.09.016"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002727?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012001081?idApp=UINPBA000044"
      "url" => "/00017310/0000010300000008/v1_201304241522/S0001731012001081/v1_201304241522/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219012002909"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2012.03.020"
    "estado" => "S300"
    "fechaPublicacion" => "2012-10-01"
    "aid" => "648"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2012;103:708-17"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2420
      "formatos" => array:3 [
        "EPUB" => 48
        "HTML" => 1741
        "PDF" => 631
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Oral Propranolol for Treating Infantile Hemangiomas&#58; A Case Series of 57 Patients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "708"
          "paginaFinal" => "717"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Propranolol oral en el Tratamiento de los Hemangiomas de la Infancia&#58; Serie de 57 pacientes"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0010"
          "etiqueta" => "Figure 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 342
              "Ancho" => 1000
              "Tamanyo" => 60883
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Patient number 26&#46; &#40;A&#41; Start at two months and &#40;B&#41; fifth-month follow-up&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;S&#46; Zegpi-Trueba, &#193;&#46; Abarz&#250;a-Araya, S&#46; Silva-Valenzuela, C&#46; Navarrete-Dechent, P&#46; Uribe-Gonz&#225;lez, C&#46; Nicklas-D&#237;az"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "M&#46;S&#46;"
              "apellidos" => "Zegpi-Trueba"
            ]
            1 => array:2 [
              "nombre" => "&#193;&#46;"
              "apellidos" => "Abarz&#250;a-Araya"
            ]
            2 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Silva-Valenzuela"
            ]
            3 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Navarrete-Dechent"
            ]
            4 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Uribe-Gonz&#225;lez"
            ]
            5 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Nicklas-D&#237;az"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0001731012002414"
        "doi" => "10.1016/j.ad.2012.03.010"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012002414?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002909?idApp=UINPBA000044"
    "url" => "/15782190/0000010300000008/v1_201304241323/S1578219012002909/v1_201304241323/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1578219012002569"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2012.09.003"
    "estado" => "S300"
    "fechaPublicacion" => "2012-10-01"
    "aid" => "534"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "ssu"
    "cita" => "Actas Dermosifiliogr. 2012;103:679-93"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 12598
      "formatos" => array:3 [
        "EPUB" => 57
        "HTML" => 10814
        "PDF" => 1727
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">REVIEW ARTICLE</span>"
      "titulo" => "Congenital Syphilis in the 21st Century"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "679"
          "paginaFinal" => "693"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "S&#237;filis cong&#233;nita en el siglo <span class="elsevierStyleSmallCaps">xxi</span>"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1260
              "Ancho" => 2262
              "Tamanyo" => 180829
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">New cases of congenital syphilis in each autonomous community in Spain&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C&#46; Rodr&#237;guez-Cerdeira, V&#46;G&#46; Silami-Lopes"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Rodr&#237;guez-Cerdeira"
            ]
            1 => array:2 [
              "nombre" => "V&#46;G&#46;"
              "apellidos" => "Silami-Lopes"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731011005278"
        "doi" => "10.1016/j.ad.2011.10.008"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731011005278?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002569?idApp=UINPBA000044"
    "url" => "/15782190/0000010300000008/v1_201304241323/S1578219012002569/v1_201304241323/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Novelties in Dermatology</span>"
    "titulo" => "Treatment of Cutaneous Lymphomas&#58; an Update"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "694"
        "paginaFinal" => "707"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "R&#46;M&#46; Izu-Belloso, J&#46;C&#46; Garc&#237;a-Ruiz"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "R&#46;M&#46;"
            "apellidos" => "Izu-Belloso"
            "email" => array:1 [
              0 => "rizu&#64;ya&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">¿</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "J&#46;C&#46;"
            "apellidos" => "Garc&#237;a-Ruiz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital de Basurto&#44; Bilbao&#44; Spain"
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a y Hemoterapia&#44; Hospital de Cruces&#44; Barakaldo&#44; Bizkaia&#44; Spain"
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Coorresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Actualizaci&#243;n terap&#233;utica en linfomas cut&#225;neos"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Primary cutaneous lymphomas &#40;PCLs&#41; are a heterogeneous group of lymphoid malignancies that originate primarily in the skin&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Most &#40;75&#37;&#41; are derived from T cells &#40;primary cutaneous T-cell lymphoma &#91;CTCL&#93;&#41; while 20&#37; to 25&#37; are derived from B cells &#40;primary cutaneous B-cell lymphoma &#91;CBCL&#93;&#41;&#46; Mycosis fungoides &#40;MF&#41; and S&#233;zary syndrome &#40;SS&#41; are the most common such PCLs&#46; It is important to differentiate PCLs from their equivalent lymph node disease&#44; given that they show clinical and histopathologic differences and have different immunophenotypes and a different molecular biology&#46; Most importantly&#44; PCLs have a more indolent course in most cases and different treatment regimens are used&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">For a correct diagnosis and hence appropriate treatment&#44; it is necessary to be familiar with the latest classifications such as those of the European Organisation for Research and Treatment of Cancer &#40;EORTC&#41;&#47;World Health Organization &#40;WHO&#41;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41; and the WHO &#40;2008&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2&#44;3</span></a> PCLs have a very low incidence&#44;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> and most patients survive for a long time&#46; It is therefore difficult to assess the impact of a given treatment on outcome and there are almost no case-control studies to guide us&#46; The levels of evidence are therefore low&#46; Ideally&#44; all patients with PCLs would be included in a clinical trial&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Many therapeutic options are available for the management of PCL&#46;<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5&#44;6</span></a> The choice of treatment should be based mainly on the clinical stage&#44; but other factors should also be considered such as access to treatments&#44; age and general health of the patient&#44; and cost-benefit ratio&#46; In the initial stages of the disease&#44; no data are available to demonstrate the superiority of systemic treatment &#40;the more aggressive option&#41; over local treatment targeting the skin lesions&#46; A conservative approach is therefore recommended&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">The treatments can be divided into 2 broad groups&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1</span><p id="par0025" class="elsevierStylePara elsevierViewall">Treatments that target the skin and act only on the population of neoplastic cells in the skin&#46; In this case&#44; the adverse effects are usually less severe than those arising with systemic treatments&#46; This type of treatment is in practice the only one recommended for first-line treatment of early phases of MF&#46; In advanced stages&#44; it is still an important option&#44; forming part of combination therapies&#46; Such treatments include&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0030" class="elsevierStylePara elsevierViewall">Topical corticosteroids</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">-</span><p id="par0035" class="elsevierStylePara elsevierViewall">Alkylating agents&#58; topical nitrogen mustard &#40;mechlorethamine&#41; and carmustine</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">-</span><p id="par0040" class="elsevierStylePara elsevierViewall">Narrow-band UV-B phototherapy&#44; psoralens<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>UV-A &#40;PUVA&#41;&#44; and other types of phototherapy</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">-</span><p id="par0045" class="elsevierStylePara elsevierViewall">Radiotherapy &#40;conventional and electron beam&#41;</p></li></ul></p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">2</span><p id="par0050" class="elsevierStylePara elsevierViewall">Systemic treatments&#44; which include biological response modifiers &#40;such as retinoids&#44; cytokines&#44; immunotoxins and vaccines&#44; monoclonal antibodies&#44; and histone deacetylase inhibitors&#41;&#44; chemotherapy &#40;traditional single- or multiagent chemotherapy or polychemotherapy&#44; new chemotherapies&#41;&#44; and allogeneic stem cell transplantation&#46;</p></li></ul></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Treatments That Target the Skin</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Topical Corticosteroids</span><p id="par0055" class="elsevierStylePara elsevierViewall">Corticosteroids are able to induce apoptosis in most neoplastic lymphocytes in the skin and reduce the number of Langerhans cells&#44; thereby interfering with the stimulation of neoplastic cells&#46; Although such treatments have been in use for years&#44; there are few studies of their use&#46;<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7&#44;8</span></a> Zackheim et al&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> reported their experience in 79 patients with MF in the form of patches or plaques&#46; Patients received medium- and high-potency corticosteroids &#40;class I-III&#41;&#44; sometimes with an occlusive dressing&#46; In patients with stage T1 disease&#44; 63&#37; had complete response &#40;CR&#41; and 31&#37; had partial response &#40;PR&#41;&#44; while in patients with stage T2 disease&#44; 25&#37; had CR and 57&#37; had PR&#46; The adverse effects observed were adrenal suppression in 10 patients&#44; skin irritation in 2&#44; and skin atrophy with stretch marks in 1 patient&#46; The authors concluded that the treatment is well tolerated and effective in the very incipient stages of the disease&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Alkylating Agents</span><p id="par0060" class="elsevierStylePara elsevierViewall">Alkylating agents are drugs that act on different mechanisms and functions of DNA&#44; thereby finally inducing cell death&#46;</p><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Topical Mechlorethamine &#40;Nitrogen Mustard&#41;</span><p id="par0065" class="elsevierStylePara elsevierViewall">Although the exact mechanism of action of mechlorethamine is unknown&#44; when administered systematically&#44; it acts as an alkylating agent with an antimitotic effect&#46; Its topical activity&#44; however&#44; appears to be mediated by immune mechanisms or by interaction with Langerhans cells&#46; The drug is usually used as an aqueous solution with a strength of 10-20<span class="elsevierStyleHsp" style=""></span>mg&#47;100<span class="elsevierStyleHsp" style=""></span>mL or as a gel &#40;10-20<span class="elsevierStyleHsp" style=""></span>mg&#47;100<span class="elsevierStyleHsp" style=""></span>g petroleum jelly&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#8211;15</span></a> An ongoing randomized&#44; double-blind&#44; multicenter trial is comparing the safety and efficacy of 2 preparations of nitrogen mustard &#40;0&#46;02&#37; in propylene glycol and 0&#46;02&#37; in petroleum jelly&#41; in patients with stage I or IIA MF refractory to topical corticosteroids&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> The preliminary results have shown similar efficacy &#40;overall response rate &#91;ORR&#93; of around 70&#37;&#41; and a good safety profile &#40;no systemic absorption was seen&#41; for both preparations&#46; In clinical practice&#44; the drug is initially applied daily until the lesions have cleared &#40;in 3 to 6 months with the solution and 6 to 12 months with the gel&#41;&#46; An intermittent maintenance regimen is followed thereafter&#46; Application to the entire body surface is usually recommended&#44; though avoiding intertriginous areas&#46; However&#44; the need to treat unaffected areas is not very clear&#46; Response varies between 50&#37; and 75&#37; in stage T1 and 25&#37; and 50&#37; in stage T2&#46; Contact dermatitis &#40;allergic or irritant&#41; may arise&#44; particularly when using the aqueous solution &#40;30&#37; vs <span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5&#37; with the gel&#41;&#46; Urticaria and anaphylactic reactions have also been reported&#46; Prolonged use increases the risk of nonmelanoma skin cancer&#44; particularly if the patients have received prior PUVA or total skin electron beam therapy&#46; In general&#44; myelosuppression or other systemic effects do not occur&#46; Efficacy appears to be similar for the 2 preparations &#40;solution and gel&#41;&#44; although prospective studies comparing the 2&#44; other than the one described above&#44;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> have not been undertaken&#46; In recent years&#44; the availability of mechlorethamine in hospital pharmacies has been limited&#44; and so it is unfortunately being used less and less despite its efficacy&#46;</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Carmustine</span><p id="par0070" class="elsevierStylePara elsevierViewall">Carmustine is an alkylating agent that induces cell death through inhibition of DNA synthesis&#46; It is used as an alcohol solution &#40;2<span class="elsevierStyleHsp" style=""></span>mg&#47;mL&#41; or as an ointment&#46;<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17&#8211;20</span></a> It should be applied daily to the lesioned skin&#44; and the clearance time is similar to that of mechlorethamine&#46; Response rates vary from 86&#37; in stage T1 to 48&#37; in stage T2&#46; Most patients experience erythema&#44; sometimes followed by persistent telangiectasia&#44; and approximately 3&#37; to 5&#37; develop mild leukopenia due to myelosuppression&#46; The agent can be used as an alternative in patients who are allergic to mechlorethamine&#44; although the availability of carmustine is also limited&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Phototherapy</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Narrow-Band UV-B Phototherapy &#40;311-312<span class="elsevierStyleHsp" style=""></span>nm&#41;</span><p id="par0075" class="elsevierStylePara elsevierViewall">Several studies have shown the usefulness of narrow-band UV-B phototherapy in the initial stages of MF &#40;CR rates of around 75&#37;&#44; with a mean response duration of 51 months&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21&#8211;26</span></a> The risk of skin cancer is increased&#44; however&#44; and therapy is only effective in MF with incipient lesions with little or no infiltration&#44; given the limited penetration of the radiation&#46; This type of therapy is considered particularly useful in those patients who do not tolerate psoralens&#44; those with very light skin&#44; and those with very incipient lesions&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Psoralens Plus UV &#40;320-400<span class="elsevierStyleHsp" style=""></span>nm&#41;</span><p id="par0080" class="elsevierStylePara elsevierViewall">PUVA is the classic treatment in the early stages of lymphatic disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20&#44;29&#8211;34</span></a> Usually&#44; the patient starts with 2 to 3 weekly sessions&#44; with the interval between sessions being reduced according to response&#46; There is no consensus about whether it is necessary to follow a maintenance regimen once CR has been achieved&#46;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> In a study of 82 patients with MF in the form of superficial plaques and&#47;or palpable plaques&#44; CR was obtained in 65&#37; and PR in 30&#37;&#44; with a mean response duration of 43 months&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Chronic actinic damage was observed in 10&#37; of the patients&#44; with the appearance of carcinomas in 6 patients&#58; 3 with basal cell carcinoma and 3 with squamous cell carcinoma&#46; Although there are studies that show a statistically significant increase in carcinogenesis&#44; including melanoma&#44; we believe that this risk is more theoretical than real&#44; at least in this group of patients&#46; According to the most recent studies&#44; the disease-free interval is related to a higher cumulative dose of PUVA and longer treatment times&#46;<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">27&#44;35</span></a> Although late recurrences are seen&#44; between 30&#37; and 50&#37; of patients in stages IA&#44; IB&#44; and IIA can maintain CR for periods of up to 10 years&#46; The disease-free survival at 5 and 10 years for patients in stage IA was 56&#37; and 30&#37;&#44; respectively&#46; For those patients in stages IB&#47;IIA&#44; 5- and 10-year disease-free survival was 74&#37; and 50&#37;&#44; respectively&#46; However&#44; the overall survival did not vary significantly between those with recurrences and those without&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Others Types of Phototherapy</span><p id="par0085" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">-</span><p id="par0090" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Extracorporeal photopheresis&#46;</span><a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">36&#8211;39</span></a> In a modification of PUVA&#44; after ingestion of psoralen&#44; circulating mononuclear cells from the patient are exposed to UV-A&#46; The main drawback of this approach is the high cost and&#44; in addition&#44; efficacy is no better than other treatments&#46; The best responses are obtained in patients with early-stage SS who have normal CD8 counts and have not received prior aggressive therapies&#46;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">-</span><p id="par0095" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Hypericin</span>&#46; This new photodynamic plant derivative induces T-lymphocyte apoptosis in association with visible or UV-A light&#46; If preliminary results are confirmed&#44; this option could be better than the other forms of phototherapy&#44;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">40</span></a> as visible light does not increase the risk of skin cancer&#46;</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">-</span><p id="par0100" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Photodynamic therapy</span>&#46; The use of photodynamic therapy with derivatives of 5-aminolevulinic acid could be particularly appropriate in patients with few lesions or lesions on the scalp&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">41</span></a></p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">-</span><p id="par0105" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Monochromatic excimer laser light</span>&#46; Excimer lasers at a wavelength of 308<span class="elsevierStyleHsp" style=""></span>nm have also been used and are approved by the US Food and Drug Administration &#40;FDA&#41; for psoriasis and vitiligo&#46; Passeron et al&#46;<a class="elsevierStyleCrossRefs" href="#bib0210"><span class="elsevierStyleSup">42&#44;43</span></a> have performed a clinical trial in which good responses were obtained in very incipient lesions&#46; This approach can therefore be considered in areas that are not usually accessible with phototherapy&#46;</p></li></ul></p><p id="par0110" class="elsevierStylePara elsevierViewall">The evidence to support these approaches is&#44; however&#44; limited&#46; Likewise&#44; there is little evidence with regard to other therapeutic options&#46;</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Radiotherapy</span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conventional &#40;Orthovoltage&#41;</span><p id="par0115" class="elsevierStylePara elsevierViewall">Conventional radiotherapy is used for highly infiltrated plaques or localized MF tumors refractory to other treatments&#46;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a> It is particularly indicated as front-line treatment of cutaneous marginal zone B-cell lymphoma and follicle center lymphoma along with excision&#46;<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">45&#44;56</span></a> The recurrence rate is higher if doses less than 30<span class="elsevierStyleHsp" style=""></span>Gy are used&#46; Local radiotherapy has also been used in solitary MF lesions with impressive results&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">47</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Total Skin Electron Radiation &#40;Electron Beam Therapy&#41;</span><p id="par0120" class="elsevierStylePara elsevierViewall">An electron beam is the treatment of choice for patients with MF with infiltrated plaques or small generalized tumors&#46; The most widely used voltage is 6 MeV&#44; and therapy is applied 4 days per week for a total dose of 3600 cGy in 10 weeks&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a> The treatment can be repeated several times if reduced doses are used&#46; Adverse effects include generalized erythema&#44; edema&#44; scaling and exudation&#44; apparent worsening of existing lesions&#44; total loss of skin appendages&#44; transverse melanonychia and&#44; less frequently&#44; blistering&#46; Hair loss is usually reversible if the total dose administered has not exceeded 2500&#160;cGy&#46; In the longer term&#44; patients may develop edema&#44; hyperpigmentation&#44; telangiectasia&#44; and persistent xerosis&#44; while men may become sterile&#46;<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">48&#8211;50</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">The disease-free interval can be extended according to some authors by subsequent maintenance therapy&#44; either with mustard derivatives or PUVA&#46;<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">48&#44;49&#44;51&#44;52</span></a> The recommendations of the EORTC on total skin electron radiation in MF were published in 2002&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a> The procedure is not recommended for erythrodermic CTCL &#40;T3&#41; given the risk of severe scaling and because the CR rates are higher in the earlier stages &#40;CR of 90&#37; in T1 and 70&#37; in T2 disease&#41; than in the more advanced stages&#44; where the effect is only palliative&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">It is known that CR rate depends on the stage of the disease&#44; the dose applied&#44; and the electron energy&#46;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> Overall&#44; CR rates of 96&#37; are obtained in patients with stage IA&#44; IB&#44; and IIA disease&#59; of 36&#37; in those with stage IIB disease&#59; and of 60&#37; or less in patients with stage III disease&#46; CR rates are also related to total dose &#40;32-36<span class="elsevierStyleHsp" style=""></span>Gy&#41; and electron energy &#40;4-6 MeV&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0260"><span class="elsevierStyleSup">52&#44;53</span></a></p></span></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Systemic Treatments</span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Biological Response Modifiers</span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Retinoids</span><p id="par0135" class="elsevierStylePara elsevierViewall">Isotretinoin and etretinate have been used in the treatment of MF to similar effect&#46; Their usefulness as monotherapy is limited&#44; as it was seen that atypical cells were still present according to the pathology study even though the lesions had apparently healed&#46; These agents have been combined with PUVA and interferon alfa &#40;IFN-&#945;&#41;&#46; When combined with PUVA&#44; they seem to be able to reduce the UV-A dose while with IFN-&#945; they seem to enhance the response to interferon in early but not late disease stages&#46; However&#44; there are no randomized studies that compare IFN-&#945; and IFN-&#945; in combination with retinoids&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">Bexarotene is a new retinoid &#40;more specifically a rexinoid&#41; whose exact mechanism of action is unknown although it inhibits growth of tumor lymphocytes and also enhances apoptosis in vitro&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">55</span></a> Bexarotene selectively activates RXR receptors &#40;a type of nuclear receptor activated by retinoic acid&#41;&#44; acting as a regulator of cell differentiation and proliferation&#46; In 2002&#44; the FDA approved the compound&#44; both for topical use as a 1&#37; gel &#40;which has so far not been marketed in Spain but can be obtained as an imported medicine&#41; and for systemic use at an optimum dose of 300<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#47;d&#46; Regular laboratory testing should be performed during treatment&#44; focusing mainly on triglyceride levels and thyroid hormones&#46; Bexarotene induces hypertriglyceridemia&#44; which can be marked at times&#46; Preventive treatment should therefore be given the preceding week with statins or a fenofibrate but not with gemfibrozil as this fibrate increases the levels of bexarotene in blood&#44; probably through inhibition of cytochrome P450&#46; Hypothyroidism is another common adverse effect that can be controlled with administration of thyroid hormone&#46; Bexarotene can be combined with other treatments such as PUVA or IFN-&#945;&#46; It may also find uses in a maintenance regimen after more aggressive therapies in patients with more advanced disease&#46; As with other retinoids&#44; it requires contraceptive measures in view of the risk of malformations&#46;<a class="elsevierStyleCrossRefs" href="#bib0280"><span class="elsevierStyleSup">56&#8211;61</span></a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Interferon-alfa</span><p id="par0145" class="elsevierStylePara elsevierViewall">IFN-&#945; is used as monotherapy administered subcutaneously &#40;although intramuscular and intralesional administration is also possible&#41; at a dose of 3 to 20 million units per day&#44; 3 days a week&#44; with a good &#40;dose-dependent&#41; response&#44; particularly in early-stage disease &#40;ORR of approximately 70&#37;&#41; or in combination with other therapies such as PUVA &#40;apparently the most effective combination&#41;&#44; retinoids&#44; or purine analogs &#40;fludarabine&#41; with apparent benefit &#40;studies that compare these options with IFN-&#945; monotherapy are lacking&#41;&#46; Adverse effects include flu-like syndrome&#44; gastrointestinal disorders&#44; bone marrow suppression&#44; and elevated transaminases&#46; The agent can be used for years as maintenance in patients who showed a good response and are at risk of relapse&#44; although there is a risk of developing autoimmune diseases such as diabetes mellitus&#44; thyroiditis&#44; or hemolytic anemia&#46;<a class="elsevierStyleCrossRefs" href="#bib0310"><span class="elsevierStyleSup">62&#8211;64</span></a></p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Immunotoxins</span><p id="par0150" class="elsevierStylePara elsevierViewall">Denileukin diftitox &#40;DAB<span class="elsevierStyleInf">389</span>-interleukin 2 &#91;IL-2&#93;&#41; is the first fusion cytotoxin approved by the FDA for the treatment of CTCL&#46;<a class="elsevierStyleCrossRefs" href="#bib0325"><span class="elsevierStyleSup">65&#44;66</span></a> It acts as a specific cytotoxin for cells that express the IL-2 receptor&#46; It is obtained by expression in <span class="elsevierStyleItalic">Escherichia coli</span> of the product of fusion of the human IL-2 receptor genes with cytotoxic sequences of diphtheria toxin&#46; The agent binds to the IL-2 receptor &#40;CD25&#41; of T lymphocytes&#44; thereby inhibiting protein synthesis&#44; and is administered intravenously at a dose of 9 or 18<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d in 5-day cycles every 3 weeks&#46; It has been shown to be particularly effective in stage IIB MF &#40;response rate&#44; 38&#37;&#41;&#46; Transient flu-like syndrome is reported in 60&#37; to 70&#37; of the patients&#44; a similar figure to that seen with IFN-&#945;&#46; Other adverse effects such as urticaria&#44; anaphylaxis&#44; or vascular leak syndrome have also been reported&#46; Some patients developed anti-DAB<span class="elsevierStyleInf">389</span> or anti-IL-2 antibodies in the first cycle&#44; but there was no correlation with either toxicity or response&#46; Efficacy has been boosted in recent studies through the concomitant use of oral bexarotene&#44; particularly in patients with low or nonexistent expression of the IL-2 receptor&#46;<a class="elsevierStyleCrossRefs" href="#bib0335"><span class="elsevierStyleSup">67&#44;68</span></a> Combination therapy enabled lower doses of the 2 treatments to be used&#46; The agent has been used in monotherapy in CTCLs other than MF&#44;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">69</span></a> and in combination with radiotherapy&#46;<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">70</span></a></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Monoclonal Antibodies</span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Alemtuzumab</span><p id="par0155" class="elsevierStylePara elsevierViewall">Alemtuzumab is a humanized monoclonal antibody that targets the CD52 glycoprotein expressed on the surface of T and B lymphocytes&#44; natural killer &#40;NK&#41; cells&#44; and to a lesser extent on monocytes and macrophages&#46; The mechanism of action has not been fully elucidated but involves direct complement-mediated cell lysis and also antibody-dependent cytotoxicity and apoptosis&#46; In 2003&#44; its usefulness was demonstrated in 22 patients with pretreated MF&#47;SS&#44; most of whom had advanced disease &#40;86&#37;<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>stage III and 36&#37; with B symptoms&#41; and a general poor state of health&#46; The ORR was 55&#37; &#40;32&#37; CR&#41; and the mean response duration was 12 months&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">71</span></a> Recently&#44; these encouraging outcomes have been reproduced&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">72</span></a> Alemtuzumab-induced cytopenia is potentially the most serious complication reported&#46; Although different degrees of anemia and&#47;or thrombocytopenia may develop due to mechanisms that are not well understood&#44; T- and B-cell lymphopenia is a generalized finding in all patients&#46; This predisposes them to serious opportunistic infections &#40;particularly by cytomegalovirus and <span class="elsevierStyleItalic">Pneumocystis jirovecii</span>&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">73</span></a> Alemtuzumab seems especially useful in the management of pruritus associated with the erythrodermic forms &#40;SS&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">74&#44;75</span></a></p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Zanolimumab</span><p id="par0160" class="elsevierStylePara elsevierViewall">Zanolimumab is another monoclonal antibody&#44; which targets the CD4 receptor expressed on T lymphocytes and macrophages&#46; It interferes with T-cell activation by impeding the interaction of CD4 with class II molecules of the major histocompatibility complex and also induces cell lysis through antibody-mediated cytotoxicity rather than by complement-mediated effects as is the case with alemtuzumab&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">76&#44;77</span></a> Zanolimumab has been shown to be effective in 2 phase II multicenter studies of 47 patients with heavily pretreated persistent and refractory CTCL &#40;38 MF and 9 SS&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">78</span></a> The arms in which high doses of zanolimumab were administered &#40;560<span class="elsevierStyleHsp" style=""></span>mg&#47;wk for early stages &#91;MF&#44; stages IB-IIA&#93; and 980<span class="elsevierStyleHsp" style=""></span>mg&#47;wk for advanced stages &#91;MF&#44; stages IIB-IVB&#44; and SS&#93;&#41; achieved an ORR of 56&#37; with an impressive mean duration of response of 81 weeks &#40;particularly in MF&#41;&#46; Overall&#44; zanolimumab has an acceptable safety profile with moderate adverse effects such as dermatitis&#44; eczemas&#44; and infections limited to the skin and upper respiratory tract despite the severe CD4 cell depletion associated with its use&#46; No differences were observed in the incidence of infection between the 2 different dose groups&#46; Although a more marked CD4 cell depletion was observed among patients treated at the higher dose &#40;560-980 vs 280<span class="elsevierStyleHsp" style=""></span>mg&#47;wk&#41;&#44; of note was that there were no statistically significant differences in CD4 cell recovery once treatment had finished&#46; On the basis of these findings&#44; a pivotal phase III study was started and is currently in progress&#46;</p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Rituximab</span><p id="par0165" class="elsevierStylePara elsevierViewall">Rituximab is a chimeric &#40;human-murine&#41; anti-C20 monoclonal antibody that is used as monotherapy or in combination with other agents mainly for the treatment of systemic non-Hodgkin B-cell lymphoma&#46; Several studies have found it to be effective when administered intralesionally in patients with CBCL &#40;marginal zone and follicle center cell types&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">45&#44;46&#44;79&#44;80</span></a> It is considered particularly useful in patients with multiple lesions or those with a high risk of recurrence&#44; as well as in areas where we wish to avoid the unsightly sequelae of surgery and&#47;or radiotherapy&#46; It is also used in combination with cyclophosphamide&#44; vincristine&#44; and prednisone with doxorubicin &#40;CHOP&#41; for CBCL&#44; leg-type&#46;</p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Histone Deacetylase Inhibitors</span><p id="par0170" class="elsevierStylePara elsevierViewall">Histones are proteins present in abundance in cell nuclei&#44; where they form the chromatin of eukaryotic cells along with other types of proteins and DNA&#46; In recent years&#44; several molecules within the pharmacologic group of histone deacetylase inhibitors have been developed&#44; encouraged by different experimental findings that suggest that excess histone acetylation occurs in most cancers&#46;<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">81&#44;82</span></a> Four histone deacetylase inhibitors have been studied in the treatment of CTCL&#58; vorinostat&#44; romidepsin&#44; panobinostat&#44; and belinostat&#46;</p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Vorinostat</span><p id="par0175" class="elsevierStylePara elsevierViewall">Vorinostat has been authorized by the FDA for the treatment of skin manifestations of patients with CTCL which persist&#44; progress&#44; or recur after at least 2 systemic treatments&#46;<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">83</span></a> However&#44; the drug has not been marketed in Europe&#46; The indication was established after a phase II study of 74 patients with MF&#47;SS&#46;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">84</span></a> Most of these patients had advanced disease stages &#40;61 patients with <span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>IIB disease and 30 patients with SS&#44; while 22 patients had clinically abnormal lymph nodes&#41;&#46; All patients had received intensive treatment &#40;96&#37; with bexarotene&#44; 63&#37; with IFN-&#945;&#44; 61&#37; with chemotherapy&#44; 36&#37; with photophoresis&#44; and 31&#37; with denileukin diftitox&#41;&#46; The dose was 400<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#44; administered orally&#44; with adjustment or suspension according to toxicity or adverse effects&#46; Overall&#44; 29&#46;7&#37; achieved response&#46; Among patients with advanced disease &#40;IIB or worse&#41;&#44; 29&#46;5&#37; achieved response&#46; Among patients with SS&#44; 33&#46;3&#37; achieved response&#46; Vorinostat was generally well tolerated and the adverse effects observed most frequently were gastrointestinal &#40;nausea&#44; diarrhea&#41; and constitutional &#40;asthenia&#44; anorexia&#44; and weight loss&#41;&#46; Cytopenias &#40;thrombocytopenias and anemia&#41; were also frequently reported&#46; Neutropenia was not observed&#46; Fewer than 15&#37; of the patients required a reduction in vorinostat dose and 11&#37; had serious adverse effects&#44; which were mainly thromboembolic phenomena&#46; QT prolongation was only observed in 3 patients&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">Recent studies are using these agents in combination with other therapies such as bexarotene<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">85</span></a> or IFN-&#945;&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">86</span></a></p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Romidepsin</span><p id="par0185" class="elsevierStylePara elsevierViewall">Romidepsin is a new and potent histone deacetylase inhibitor that has been used in patients with CTCL and peripheral T-cell lymphomas&#46; Several studies have demonstrated its usefulness&#44;<a class="elsevierStyleCrossRefs" href="#bib0435"><span class="elsevierStyleSup">87&#8211;90</span></a> with an ORR of 41&#37; &#40;7&#37; with CR and 33&#37; with PR&#41;&#44; a median response duration of 14&#46;9 months&#44; and a median time to progression of 8&#46;3 months&#46; The most frequently observed adverse effects were nausea&#44; asthenia&#44; and vomiting&#46; Adverse effects grade 3 or worse were only observed in 33&#37; of the patients&#46; The most frequently observed adverse effects were disease progression &#40;6&#37;&#41;&#44; fever &#40;3&#37;&#41;&#44; sepsis &#40;2&#37;&#41;&#44; tumor lysis syndrome &#40;2&#37;&#41;&#44; and hypotension &#40;2&#37;&#41;&#46; Six patients died&#44; one possibly of treatment-related causes&#46; QT prolongation was only observed in 2&#37; of the patients &#40;patients with significant cardiac abnormalities and&#47;or those in treatment with QT prolonging agents or inhibitors of cytochrome P3A4 were excluded from the study&#41;&#46;</p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Panobinostat</span><p id="par0190" class="elsevierStylePara elsevierViewall">The new histone deacetylase inhibitor&#44; panobinostat&#44; not only produces histone acetylation but also induces p21&#44; cell cycle arrest&#44; apoptosis&#44; and HSP90 &#40;pan-histone deacetylase inhibitor&#41; acetylation&#46; Its usefulness and safety profile have been demonstrated recently in a phase II study performed in 40 patients with CTCL refractory to at least 2 prior treatments &#40;mean of 5 prior treatments per patient&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">91</span></a> Patients received 20<span class="elsevierStyleHsp" style=""></span>mg&#47;d of panobinostat orally on days 1&#44; 3&#44; and 5 of each week until disease progression or intolerance&#46; The response rates were poor&#46; In patients who had received prior treatment with bexarotene &#40;group 1&#44; 25 patients&#41;&#44; PR was obtained in 3 and 4 had stable disease&#46; Three patients had progression&#46; Thirty patients could not be evaluated because of limited follow-up at the time of publication&#46; The most frequently observed adverse effects were diarrhea&#44; thrombocytopenia&#44; fatigue&#44; asthenia&#44; hypertriglyceridemia&#44; taste alterations&#44; nausea&#44; and pruritus &#40;15&#37; of all patients&#41;&#46; No significant QT prolongations were observed&#46;</p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Belinostat</span><p id="par0195" class="elsevierStylePara elsevierViewall">Belinostat is another pan-histone deacetylase inhibitor that has been tested in a phase II clinical trial with 29 patients &#40;15 with MF&#44; 7 with SS&#44; 5 without either MF or SS&#44; and 2 with unclassified disease&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">92</span></a> The participants received 1000<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span> in a 30-minute infusion from day 1 to 5 of each cycle&#44; every 3 weeks&#46; Seventeen patients achieved stable disease for longer than 127 days&#46; There were 2 PR and 2 CR with a median response duration of 273 days&#46; It is important to note that the time to response was very short&#58; 16 days &#40;range&#44; 14-35 days&#41; with a substantial improvement in pruritus&#46; There were no reports of grade 4 hematologic toxicity or cases of grade 3 QT prolongation&#46; Four grade 3 or 4 adverse effects were observed&#58; pruritus&#44; erythema&#44; edema&#44; and adynamic ileus&#46;</p></span></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Others</span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Bortezomib</span><p id="par0200" class="elsevierStylePara elsevierViewall">Bortezomib is a drug indicated as first-line treatment in patients with multiple myeloma who are not candidates for hematopoietic stem cell transplantation and in patients with a relapse after prior treatment&#46; The group at the Hematology Institute of the University of Bologna in Italy conducted a phase II study of 12 patients &#40;10 with advanced MF and 2 with peripheral T-cell lymphomas with isolated cutaneous involvement&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">93</span></a> They reported an ORR of 67&#37;&#44; including 2 CR &#40;17&#37;&#41; and 6 PR &#40;50&#37;&#41;&#46; One patient with MF and 1 with peripheral T-cell lymphoma achieved CR &#40;10&#37; and 50&#37;&#44; respectively&#41;&#46; CR lasted for more than 1 year after the last study dose in the patient with MF while relapse was observed 10 months later in the patient with peripheral T-cell lymphoma&#46; The regimen of bortezomib used was the same as for multiple myeloma&#58; 1&#46;3<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#44; given intravenously on days 1&#44; 4&#44; 8&#44; and 11 of each 21-day cycle up to a total of 6 cycles&#46; The adverse effects observed most frequently were neutropenia &#40;2 patients &#91;17&#37;&#93;&#44; WHO grade 3&#41;&#44; thrombocytopenia &#40;2 patients &#91;17&#37;&#93;&#44; WHO grade 3&#41;&#44; and sensory neuropathy &#40;2 patients &#91;17&#37;&#93;&#44; WHO grade 3&#41;&#46; No infections or treatment-related deaths were reported during the study&#46; The rationale for using bortezomib is that it can act as an inhibitor of nuclear factor &#954;B &#40;NF-&#954;B&#41;&#44; which is constitutively activated in CTCL cell lines&#44; and induce apoptosis&#46;<a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">94</span></a> NF-&#954;B is a transcriptional factor implicated in the generation of inflammatory responses&#44; regulation of the cell cycle&#44; and protection against apoptosis&#46;</p></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Lenalidomide</span><p id="par0205" class="elsevierStylePara elsevierViewall">The antitumor effects of lenalidomide are attributed to several mechanisms of action&#58; inhibition of the production of proinflammatory mediators by monocytes &#40;tumor necrosis factor &#945;&#44; IL-1&#44; IL-6&#44; IL-12&#41;&#44; enhancement of IL-2 and IFN-&#947; production by T lymphocytes&#44; and enhancement of the cytotoxic activity of these cytokines and NK cells&#46; In a phase II study&#44; lenalidomide was administered at a dose of 10 to 25<span class="elsevierStyleHsp" style=""></span>mg&#47;d for 21 days in cycles of 28 days to 25 patients with extensively pretreated CTCL &#40;mean of 6 prior regimens&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">95</span></a> Seven patients achieved PR after a mean of 9 cycles of treatment&#46; The adverse effects observed most frequently were anemia&#44; scaling&#44; pruritus&#44; and leg edema&#46; In the high-dose group&#44; intense neutropenia was observed in 2 patients while 1 patient discontinued treatment due to dysarthria&#46;</p></span></span></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Chemotherapy</span><p id="par0210" class="elsevierStylePara elsevierViewall">Chemotherapy should only be used in CTCL in advanced stages of the disease&#44; as it is no more effective than conservative treatment in the early phases&#46; Almost all chemotherapy agents used for systemic lymphomas have also been used in advanced CTCL&#58; alkylating agents&#44; methotrexate&#44; cisplatin&#44; etoposide&#44; bleomycin&#44; vinblastine&#44; cyclophosphamide&#46; It is not clear whether one agent is any better than another and&#44; in general&#44; responses are short-lasting&#46; The most effective combination&#44; and therefore the most widely used one&#44; is CHOP or CHOP without doxorubicin &#40;CVP&#41;&#44; but randomized studies have not been undertaken that demonstrate increased survival with any of these regimens&#46;</p><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Methotrexate</span><p id="par0215" class="elsevierStylePara elsevierViewall">Methotrexate is the first-choice treatment in CD30<span class="elsevierStyleSup">&#43;</span> CTCL&#44; particularly when the patient has multiple lesions &#40;radiotherapy is the best alternative in solitary lesions&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">96</span></a> High weekly doses are required in some cases to achieve CR&#44; with a higher risk of adverse effects&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">Recently&#44; 2 other chemotherapies &#40;gemcitabine and pegylated liposomal doxorubicin &#91;DOX-PEG&#93;&#41; have been shown to be useful in monotherapy&#46;</p></span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Gemcitabine</span><p id="par0225" class="elsevierStylePara elsevierViewall">Gemcitabine is a pyrimidine antimetabolite indicated for solid tumors traditionally considered resistant to conventional treatment such as lung cancer&#44; ovarian cancer&#44; pancreatic cancer&#44; and urinary bladder cancer&#46; Its effectiveness in cutaneous lymphomas has been investigated in 2 studies&#46; The first to these was a series of 32 patients &#40;mostly with MF&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">97</span></a> CR was achieved by 22&#37; &#40;7 patients&#41; while PR was achieved by 53&#37; &#40;17 patients&#41;&#46; Unfortunately&#44; the study used standard criteria for assessing response as if the patients had common forms of non-Hodgkin lymphoma and not specifically cutaneous lymphoma &#40;severity-weighted assessment tool&#41;&#46; Response was achieved by 73&#37; of those with MF &#40;26 patients&#41;&#44; with 23&#37; with CR and 50&#37; with PR&#46; The only patient included with SS did not respond&#46; The median duration of CR was 10 months &#40;range&#44; 4-22 months&#41;&#46; Gemcitabine was administered as an intravenous infusion at a dose of 1200 <span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span> for 30<span class="elsevierStyleHsp" style=""></span>minutes in cycles of 28 days &#40;total of 6 cycles&#41; on days 1&#44; 8&#44; and 15 of each cycle&#46; The most frequently reported adverse effects were cytopenias&#46; Reversible liver toxicity was the most frequently reported nonhematologic adverse effect &#40;13 patients&#44; 40&#37;&#41;&#46; No treatment-related deaths were reported&#46; The second study was a series of 33 patients&#44; most of whom had heavily pretreated MF &#40;median of 5 prior regimens&#41; &#40;31 patients&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">98</span></a> Two patients had anaplastic CD30<span class="elsevierStyleSup">&#43;</span> T-cell lymphoma&#46; Compared to the first study&#44; a higher dose of gemcitabine was used &#40;1000<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#41; but the schedule of administration and number of cycles were the same&#46; Response was assessed using variables that included the area of skin involved&#44; size of lymph nodes&#44; and peripheral blood cytometry&#46; Response was achieved by 68&#37; of the patients &#40;2 with CR&#41;&#46; Myelosuppression was the most frequently observed adverse effect &#40;grade 3 in 8 of the 33 patients&#41; and 2 characteristic uremic hemolytic syndromes were diagnosed in patients with SS&#46; Other adverse effects were elevated transaminase liver enzymes&#44; mucositis&#44; lethargy&#44; fever&#44; hyperpigmentation&#44; infusion-related maculopapular rash&#44; and different types of cardiovascular events&#46; Another more recent multicenter study reported similar outcomes to the studies already discussed&#44; but with significantly greater toxicity&#46;<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">99</span></a></p></span><span id="sec0170" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Pegylated Liposomal Doxorubicin</span><p id="par0230" class="elsevierStylePara elsevierViewall">DOX-PEG is approved for the treatment of advanced ovarian cancer&#44; relapsed multiple myeloma after hematopoietic stem cell transplantation&#44; and AIDS-associated Kaposi sarcoma&#46; The usefulness of DOX-PEG has also been demonstrated in patients with CTCL in observational and retrospective studies&#46; Recently&#44; a prospective&#44; multicenter study analyzed use of this agent in 25 patients with MF and&#47;or SS in stages &#8805;<span class="elsevierStyleHsp" style=""></span>II refractory to at least 2 prior lines of treatment and in patients with CD30<span class="elsevierStyleSup">&#43;</span> large-cell CTCL&#46;<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">100</span></a> DOX-PEG was administered intravenously every 4 weeks at a dose of 40<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span>&#47;d for up to 8 cycles&#46; An objective ORR of 56&#37; was reported &#40;14&#47;25 patients with CR and 9&#47;25 with PR&#41;&#46; Response rates were high in patients with SS&#44; with 6 of the 10 &#40;60&#37;&#41; responding&#46; One of these responses was a CR&#46; Response rates were also high in transformed CTCL&#44; and 50&#37; of these responses were a CR&#46; In general&#44; more adverse effects were seen than in the previous studies&#44; with 4 episodes of serious infection and some cardiac events&#46; DOX-PEG has also been shown to have good activity in 5 CBCLs &#40;1 with marginal zone disease and 4 diffuse large-cell lymphomas&#44; leg-type&#41; in an Italian phase II pilot study &#40;dose of 20<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span> every 3 or 4 weeks&#41;&#46; An impressive prolonged CR was obtained in 4 of these patients &#40;80&#37;&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">101</span></a> In another study published recently&#44; excellent outcomes were obtained with DOX-PEG in combination with bleomycin&#44; vinblastine&#44; and dacarbazine &#40;CBVD regimen&#41; in 37 patients with advanced PCL&#44; both of T-cell origin &#40;19 patients&#41; and B-cell origin &#40;18 patients&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">102</span></a> CR rates of 88&#46;8&#37; and 100&#37;&#44; respectively&#44; were obtained&#46; Between 4 and 6 cycles of CBVD were administered in the group of CTCL whereas those with CBCL received between 2 and 6 cycles &#40;with rituximab added to the chemotherapy&#58; R-CBVD&#41;&#46; The safety profile was good&#46; Subsequent allogeneic hematopoietic stem cell transplantation was performed in 3 patients &#40;2 with CTCL and 1 with CBCL&#41;&#46;</p></span><span id="sec0175" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Other Chemotherapies</span><span id="sec0180" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Forodesine</span><p id="par0235" class="elsevierStylePara elsevierViewall">Forodesine is a purine analog that inhibits purine nucleoside phosphorylase&#46; Recruitment of patients with MF&#47;SS with refractory disease in stages &#8805;<span class="elsevierStyleHsp" style=""></span>IB to a phase II pivotal study was completed in 2010&#46; The preliminary results of this multicenter study have been published recently&#46;<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">103</span></a> The overall response rate was around 30&#37;&#46; The most frequently observed adverse effects were nausea&#44; tiredness&#44; edema&#44; dyspnea&#44; and urinary calculi&#46;</p></span><span id="sec0185" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Pralatrexate</span><p id="par0240" class="elsevierStylePara elsevierViewall">The cytotoxicity induced by pralatrexate can be 10 times greater than that of methotrexate&#44; allowing acquired tumor resistances to be overcome&#46; The agent has been shown to be active in advanced T-cell lymphomas and it is a promising drug for maintenance therapies in CTCL&#46;<a class="elsevierStyleCrossRefs" href="#bib0520"><span class="elsevierStyleSup">104&#44;105</span></a></p></span></span></span></span><span id="sec0190" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Stem Cell Transplantation</span><p id="par0245" class="elsevierStylePara elsevierViewall">Autologous stem cell transplantation can achieve high response rates but with immediate relapse &#40;mean time to relapse&#44; &#60;<span class="elsevierStyleHsp" style=""></span>100 days&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0530"><span class="elsevierStyleSup">106&#44;107</span></a> This approach is therefore only useful in certain patients as a means to improve quality of life or as a way to buy some time before moving on to other therapies&#46;</p><p id="par0250" class="elsevierStylePara elsevierViewall">Long-term CR has been achieved with allogeneic stem cell transplantation&#44; although mortality is high due mainly to graft-vs-host disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0540"><span class="elsevierStyleSup">108&#44;109</span></a> Indeed&#44; the efficacy of the technique is linked to the appearance of this event&#44; known as a graft-vs-lymphoma effect&#44;<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">110</span></a> in which the donor lymphocytes attack the tumor lymphocytes of the receptor&#44; thereby eliminating them&#46; Currently&#44; regimens are used that are not myeloablative but that are nevertheless cytoreductive prior to transplant&#44; in an attempt to improve response and reduce complications&#46; A recent study lends support to the role of this treatment for tumoral MF &#40;stage IIB&#41; and SS&#46;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">111</span></a> The survival rates are significantly higher in patients with second CR&#44; PR&#44; or progression with 3 or fewer lines of prior systemic therapy&#46; Administration of this therapy should therefore not be left too late in the course of the disease&#46; In the short term&#44; it may be the only curative treatment available&#46;</p></span><span id="sec0195" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conclusions</span><p id="par0255" class="elsevierStylePara elsevierViewall">Currently&#44; the aim in the treatment of PCL is to avoid progression to more advanced stages of the disease as&#44; at present&#44; there is no curative treatment available&#46; There are no comparative studies between different systemic treatments in patients with advanced PCL&#44; and so treatment in these patients is not at all protocolized&#46; There is still much debate concerning the management of this disease&#44; and so a conservative or <span class="elsevierStyleItalic">start low go slow</span> approach is recommended&#46;<a class="elsevierStyleCrossRefs" href="#bib0560"><span class="elsevierStyleSup">112&#44;113</span></a><a class="elsevierStyleCrossRefs" href="#tbl0010">Tables 2&#8211;8</a> summarize the recommendations of the EORTC consensus on treatment as well as staging&#46;<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20&#44;46</span></a> The recommendations of the EORTC for treatment of CTCL should be reviewed in the light of new emerging therapies&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><elsevierMultimedia ident="tbl0035"></elsevierMultimedia><elsevierMultimedia ident="tbl0040"></elsevierMultimedia></span><span id="sec0200" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conflicts of Interest</span><p id="par0260" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:2 [
          "identificador" => "xres96458"
          "titulo" => "Abstract"
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec83619"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "xres96459"
          "titulo" => "Resumen"
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec83618"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Treatments That Target the Skin"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Topical Corticosteroids"
            ]
            1 => array:3 [
              "identificador" => "sec0020"
              "titulo" => "Alkylating Agents"
              "secciones" => array:1 [
                0 => array:2 [
                  "identificador" => "sec0025"
                  "titulo" => "Topical Mechlorethamine &#40;Nitrogen Mustard&#41;"
                ]
              ]
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Carmustine"
            ]
            3 => array:3 [
              "identificador" => "sec0035"
              "titulo" => "Phototherapy"
              "secciones" => array:3 [
                0 => array:2 [
                  "identificador" => "sec0040"
                  "titulo" => "Narrow-Band UV-B Phototherapy &#40;311-312 nm&#41;"
                ]
                1 => array:2 [
                  "identificador" => "sec0045"
                  "titulo" => "Psoralens Plus UV &#40;320-400 nm&#41;"
                ]
                2 => array:2 [
                  "identificador" => "sec0050"
                  "titulo" => "Others Types of Phototherapy"
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "sec0055"
              "titulo" => "Radiotherapy"
              "secciones" => array:2 [
                0 => array:2 [
                  "identificador" => "sec0060"
                  "titulo" => "Conventional &#40;Orthovoltage&#41;"
                ]
                1 => array:2 [
                  "identificador" => "sec0065"
                  "titulo" => "Total Skin Electron Radiation &#40;Electron Beam Therapy&#41;"
                ]
              ]
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0070"
          "titulo" => "Systemic Treatments"
          "secciones" => array:2 [
            0 => array:3 [
              "identificador" => "sec0075"
              "titulo" => "Biological Response Modifiers"
              "secciones" => array:5 [
                0 => array:2 [
                  "identificador" => "sec0080"
                  "titulo" => "Retinoids"
                ]
                1 => array:2 [
                  "identificador" => "sec0085"
                  "titulo" => "Interferon-alfa"
                ]
                2 => array:2 [
                  "identificador" => "sec0090"
                  "titulo" => "Immunotoxins"
                ]
                3 => array:3 [
                  "identificador" => "sec0095"
                  "titulo" => "Monoclonal Antibodies"
                  "secciones" => array:8 [
                    0 => array:2 [
                      "identificador" => "sec0100"
                      "titulo" => "Alemtuzumab"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0105"
                      "titulo" => "Zanolimumab"
                    ]
                    2 => array:2 [
                      "identificador" => "sec0110"
                      "titulo" => "Rituximab"
                    ]
                    3 => array:2 [
                      "identificador" => "sec0115"
                      "titulo" => "Histone Deacetylase Inhibitors"
                    ]
                    4 => array:2 [
                      "identificador" => "sec0120"
                      "titulo" => "Vorinostat"
                    ]
                    5 => array:2 [
                      "identificador" => "sec0125"
                      "titulo" => "Romidepsin"
                    ]
                    6 => array:2 [
                      "identificador" => "sec0130"
                      "titulo" => "Panobinostat"
                    ]
                    7 => array:2 [
                      "identificador" => "sec0135"
                      "titulo" => "Belinostat"
                    ]
                  ]
                ]
                4 => array:3 [
                  "identificador" => "sec0140"
                  "titulo" => "Others"
                  "secciones" => array:2 [
                    0 => array:2 [
                      "identificador" => "sec0145"
                      "titulo" => "Bortezomib"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0150"
                      "titulo" => "Lenalidomide"
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "sec0155"
              "titulo" => "Chemotherapy"
              "secciones" => array:4 [
                0 => array:2 [
                  "identificador" => "sec0160"
                  "titulo" => "Methotrexate"
                ]
                1 => array:2 [
                  "identificador" => "sec0165"
                  "titulo" => "Gemcitabine"
                ]
                2 => array:2 [
                  "identificador" => "sec0170"
                  "titulo" => "Pegylated Liposomal Doxorubicin"
                ]
                3 => array:3 [
                  "identificador" => "sec0175"
                  "titulo" => "Other Chemotherapies"
                  "secciones" => array:2 [
                    0 => array:2 [
                      "identificador" => "sec0180"
                      "titulo" => "Forodesine"
                    ]
                    1 => array:2 [
                      "identificador" => "sec0185"
                      "titulo" => "Pralatrexate"
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0190"
          "titulo" => "Stem Cell Transplantation"
        ]
        8 => array:2 [
          "identificador" => "sec0195"
          "titulo" => "Conclusions"
        ]
        9 => array:2 [
          "identificador" => "sec0200"
          "titulo" => "Conflicts of Interest"
        ]
        10 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2011-08-10"
    "fechaAceptado" => "2012-01-29"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec83619"
          "palabras" => array:4 [
            0 => "Cutaneous lymphoma"
            1 => "Treatment"
            2 => "Update"
            3 => "Review"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec83618"
          "palabras" => array:4 [
            0 => "Linfoma cut&#225;neo"
            1 => "Tratamiento"
            2 => "Actualizaci&#243;n"
            3 => "Revisi&#243;n"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Primary cutaneous lymphomas &#40;PCLs&#41; are a heterogeneous group of lymphoid tumors that originate primarily in the skin&#46; Most PCLs &#40;75&#37;&#41; are T-cell lymphomas and only 20&#37; to 25&#37; involve B cells&#46; It is important to differentiate between cutaneous lymphomas and lymph node tumors given the differences in their molecular biology and clinical&#44; histopathologic&#44; and immunophenotypic features&#46; Moreover&#44; PCLs generally follow a more indolent course and require different treatments&#46;</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Many treatment options are available for managing PLC&#39;s&#46; The choice should be based primarily on the clinical stage of disease but must also take into consideration other factors&#44; such as the patient&#39;s age and general health&#44; the availability and accessibility of the treatment&#44; and the cost-benefit ratio&#46; It will be important to use a multidisciplinary approach&#44; involving a team of expert dermatologists&#44; hematologist-oncologists&#44; and radiotherapists who are familiar with this rare disease&#46; Recent years have seen the emergence of many new therapies&#44; particularly for advanced stages of the disease and for patients whose tumors have proven refractory to treatment&#46; The objective of this article is to review all the treatment options available to us&#46;</p>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Los linfomas cut&#225;neos primarios &#40;LCP&#41; constituyen un grupo heterog&#233;neo de neoplasias linfoides que se originan primariamente en la piel&#46; La mayor&#237;a &#40;75&#37;&#41; son linfomas de c&#233;lulas T y solo un 20-25&#37; se originan a partir de los linfocitos B&#46; Es importante diferenciar los LCP de sus equivalentes ganglionares&#44; dado que presentan caracter&#237;sticas cl&#237;nicas&#44; histopatol&#243;gicas&#44; inmunofenot&#237;picas y de biolog&#237;a molecular diferentes con un pron&#243;stico en la mayor&#237;a de los casos m&#225;s indolente y tratamientos diferentes&#46;</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Existen m&#250;ltiples opciones terap&#233;uticas en el manejo de los LCP&#46; La elecci&#243;n del tratamiento debe basarse principalmente en el estadio cl&#237;nico del paciente&#44; pero deben considerarse tambi&#233;n otros factores&#44; como la accesibilidad a los tratamientos&#44; la edad y el estado general del paciente o el coste-beneficio&#46; Adem&#225;s es importante el abordaje multidisciplinar de estos pacientes&#44; formando un equipo experto entre dermat&#243;logos&#44; hematoonc&#243;logos y radioterapeutas que conozcan bien esta infrecuente patolog&#237;a&#46; En los &#250;ltimos a&#241;os asistimos a la aparici&#243;n de m&#250;ltiples terapias nuevas&#44; especialmente para el tratamiento de los estadios avanzados o de pacientes refractarios a tratamientos previos&#46; El motivo de este art&#237;culo es revisar todas las alternativas terap&#233;uticas a nuestro alcance&#46;</p>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara">Please cite this article as&#58; Izu-Belloso RM&#44; Garc&#237;a-Ruiz JC&#46; Actualizaci&#243;n terap&#233;utica en linfomas cut&#225;neos&#46; Actas Dermosifiliogr&#46;2012&#59;103&#58;694-707&#46;</p>"
      ]
    ]
    "multimedia" => array:8 [
      0 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BCL&#44; B-cell lymphoma&#59; MF&#44; mycosis fungoides&#59; NK&#44; natural killer&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Cutaneous T-cell Lymphomas</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">MF and variants</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Folliculotropic MF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Pagetoid reticulosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Granulomatous slack skin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">S&#233;zary syndrome</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">CD30</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">&#43;</span></span><span class="elsevierStyleItalic">lymphoproliferative disorders</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Lymphomatoid papulosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>CD30<span class="elsevierStyleSup">&#43;</span> anaplastic lymphoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Adult T-cell leukemia&#47;lymphoma</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Panniculitis-like T-cell lymphoma</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Extranodal NK&#47;T-cell lymphoma&#44; nasal-type</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Peripheral T-cell lymphoma&#44; unspecified</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>CD8<span class="elsevierStyleSup">&#43;</span> epidermotropic lymphoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Cutaneous T-cell lymphoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>CD4<span class="elsevierStyleSup">&#43;</span> small&#47;medium-sized pleomorphic T-cell lymphoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">B-Cell Cutaneous Lymphomas</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Primary cutaneous marginal zone BCL</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Cutaneous follicle center BCL</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Diffuse large BCL&#44; leg-type</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Cutaneous diffuse large BCL&#44; other</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Intravascular diffuse large BCL</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Neoplastic Disease With Hematologic Precursors</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">CD4</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">&#43;</span></span><span class="elsevierStyleItalic">CD56</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">&#43;</span></span><span class="elsevierStyleItalic">hematodermic neoplasm</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab182525.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">World Health Organization&#47;European Organisation for Research and Treatment of Cancer Classification of Primary Cutaneous Lymphomas &#40;2005&#41;&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">In blood&#44; S&#233;zary cells are defined as lymphocytes with highly convoluted cerebriform nuclei&#46; If S&#233;zary cells cannot be used establish the tumor level B<span class="elsevierStyleInf">2</span>&#44; then 1 of the following modified criteria of the ISCL can be used along with a positive clonal rearrangement in the T-cell receptor&#58; <span class="elsevierStyleItalic">1&#41;</span> CD4<span class="elsevierStyleSup">&#43;</span> or C3<span class="elsevierStyleSup">&#43;</span> expansion with a CD4&#47;CD8 ratio of 10 or more&#59; <span class="elsevierStyleItalic">2&#41;</span> CD4<span class="elsevierStyleSup">&#43;</span> expansion with abnormal immunophenotype including loss of CD7 or CD26&#46;</p><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">T-cell clonality is defined by a polymerase chain reaction analysis or southern blotting of the gene that encodes the T-cell receptor&#46;</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Abbreviations and definitions&#58; Dutch&#44; criteria established by the Dutch Cutaneous Lymphomas Group&#59; ISCL&#44; International Society of Cutaneous Lymphoma&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Skin</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T<span class="elsevierStyleInf">1</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Limited patches&#44; papules&#44; and&#47;or plaques covering &#60;<span class="elsevierStyleHsp" style=""></span>10&#37; of the body surface area&#46; Can be staged as T<span class="elsevierStyleInf">1a</span> &#40;only patches&#41; vs T<span class="elsevierStyleInf">1b</span> &#40;plaques<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>patches&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T<span class="elsevierStyleInf">2</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Patches&#44; papules&#44; and&#47;or plaques covering &#8805;<span class="elsevierStyleHsp" style=""></span>10&#37; of the body surface area&#46; Can be staged as T<span class="elsevierStyleInf">2a</span> &#40;only patches&#41; vs T<span class="elsevierStyleInf">2b</span> &#40;plaques<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>patches&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T<span class="elsevierStyleInf">3</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">One or more tumors &#40;&#8805;<span class="elsevierStyleHsp" style=""></span>1<span class="elsevierStyleHsp" style=""></span>cm in diameter&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>T<span class="elsevierStyleInf">4</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Confluence of erythema covering &#8805;<span class="elsevierStyleHsp" style=""></span>80&#37; of the body surface area&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Lymph nodes</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">0</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No abnormal peripheral lymph nodes&#46; Biopsy not required&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">1</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Enlarged peripheral lymph nodes&#44; Dutch gr 1 or NCI LN<span class="elsevierStyleInf">0&#44;2</span> histology&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">1a</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">1b</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positive clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">2</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Enlarged peripheral lymph nodes&#44; Dutch gr 2 or NCI LN<span class="elsevierStyleInf">3</span> histology&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">2a</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">2b</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positive clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">3</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Enlarged peripheral lymph nodes&#44; Dutch gr 3-4&#44; or NCI LN<span class="elsevierStyleInf">4</span> positive or negative clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N<span class="elsevierStyleInf">x</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Enlarged peripheral lymph nodes&#44; without histologic confirmation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Visceral</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M<span class="elsevierStyleInf">o</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No visceral involvement&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M<span class="elsevierStyleInf">1</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Visceral involvement &#40;histologic confirmation needed and the affected organ should be specified&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hematologic</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>B<span class="elsevierStyleInf">0</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Absence of significant hematologic involvement &#8804;<span class="elsevierStyleHsp" style=""></span>5&#37; atypical lymphocytes &#40;S&#233;zary cells&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>B<span class="elsevierStyleInf">0a</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>B<span class="elsevierStyleInf">0b</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positive clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>B<span class="elsevierStyleInf">1</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Low hematologic involvement&#58; &#62;<span class="elsevierStyleHsp" style=""></span>5&#37; peripheral lymphocytes are atypical &#40;S&#233;zary cells&#41; but do not meet the criterion for B<span class="elsevierStyleInf">2</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>B<span class="elsevierStyleInf">1a</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>B<span class="elsevierStyleInf">1b</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positive clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>B<span class="elsevierStyleInf">2</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Extensive hematologic involvement&#58; &#8805;<span class="elsevierStyleHsp" style=""></span>1000&#47;mm<span class="elsevierStyleSup">3</span> S&#233;zary cells with positive clonality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab182521.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">TNMB Staging for Mycosis Fungoides&#47;S&#233;zary Syndrome&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">T&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">M&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IIB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IIIA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IIIB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IVA1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1-4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IVA2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1-4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IVB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1-4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab182523.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Clinical Staging and Classification of Mycosis Fungoides and S&#233;zary Syndrome&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">T</span><span class="elsevierStyleItalic">T</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">1</span></span>&#58; solitary skin lesionT<span class="elsevierStyleInf">1a</span>&#58; solitary lesion<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5<span class="elsevierStyleHsp" style=""></span>cm diameterT<span class="elsevierStyleInf">1b</span>&#58; solitary lesion<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>5<span class="elsevierStyleHsp" style=""></span>cm diameter<span class="elsevierStyleItalic">T</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">2</span></span>&#58; multiple skin lesions in 1 body region or 2 contiguous regionsT<span class="elsevierStyleInf">2a</span>&#58; all disease encompassed in 1 body region<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>15<span class="elsevierStyleHsp" style=""></span>cm diameterT<span class="elsevierStyleInf">2b</span>&#58; all disease encompassed in 1 body region &#62;<span class="elsevierStyleHsp" style=""></span>15<span class="elsevierStyleHsp" style=""></span>cm and <span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>cm in diameterT<span class="elsevierStyleInf">2c</span>&#58; all disease encompassed in 1 body region <span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>cm diameter<span class="elsevierStyleItalic">T</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">3</span></span>&#58; generalized cutaneous involvementT<span class="elsevierStyleInf">3a</span>&#58; multiple lesions affecting 2 noncontiguous body regionsT<span class="elsevierStyleInf">3b</span>&#58; multiple lesions affecting more than 3 body regions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">N</span><span class="elsevierStyleItalic">N</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">0</span></span>&#58; no clinical or pathologic lymph node involvement<span class="elsevierStyleItalic">N</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">1</span></span>&#58; involvement of 1 peripheral lymph node region that drains a region of skin involvement<span class="elsevierStyleItalic">N</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">2</span></span>&#58; involvement of 2 or more peripheral lymph node regions or a lymph node region that does not drain a region of skin involvement<span class="elsevierStyleItalic">N</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">3</span></span>&#58; involvement of central lymph nodes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">M</span><span class="elsevierStyleItalic">M</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">0</span></span>&#58; no evidence of extracutaneous non-lymph-node disease<span class="elsevierStyleItalic">M</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">1</span></span>&#58; extracutaneous non-lymph-node disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab182520.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">TNM Classification for Lymphomas Other Than Mycosis Fungoides&#47;S&#233;zary Syndrome&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl0025"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; ECP&#44; extracorporeal photophoresis&#59; IFN-&#945;&#58; interferon alfa&#59; MTX&#44; methotrexate&#59; PUVA&#44; psoralen &#43; UV-A&#59; TSEB&#44; total skin electron beam&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">MF IA-IIA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">MF IIB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">MF III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">MF IVA-IVB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">First-line&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PUVAUV-B &#40;patch lesions&#41;Topical CorticosteroidsLocal radiotherapyTSEB &#40;&#60;<span class="elsevierStyleHsp" style=""></span> 3 treatments&#41;CarmustineNitrogen mustard&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IFN-&#945;<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>PUVATSEB&#44; radiotherapyIFN-&#945;<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>retinoidsBexarotene<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>PUVA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IFN-&#945;<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>PUVAIFN-&#945;MTXTSEB&#44; radiotherapyCarmustineNitrogen mustardECBPUVA<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>retinoid&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ChemotherapyTSEB&#44; radiotherapyOral bexaroteneDenileukin diftitoxIFN-&#945;AlemtuzumabLow-dose MTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Second-line&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral bexaroteneIFN-&#945;IFN-&#945;<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>retinoidsDenileukin diftitoxLow-dose MTXIFN-&#945;<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>PUVARetinoid<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>PUVABexarotene<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>PUVA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral bexaroteneChemotherapyDenileukin diftitox&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral bexaroteneChemotherapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inclusion in clinical trials&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab182522.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Recommendations of the European Organisation for Treatment and Research of Cancer on the Treatment of Mycosis Fungoides &#40;MF&#41;&#46;</p>"
        ]
      ]
      5 => array:7 [
        "identificador" => "tbl0030"
        "etiqueta" => "Table 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; IFN-&#945;&#44; interferon alfa&#59; MTX&#44; methotrexate&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">First-line</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Extracorporeal photophoresis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IFN-&#945;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Denileukin diftitox&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Chlorambucil<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>prednisone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Second-line</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Oral bexarotene&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Chemotherapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Alemtuzumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>MTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab182519.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Recommendations of the European Organisation for Treatment and Research of Cancer on the Treatment of S&#233;zary Syndrome&#46;</p>"
        ]
      ]
      6 => array:7 [
        "identificador" => "tbl0035"
        "etiqueta" => "Table 7"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; CHOP&#44; cyclophosphamide&#44; vincristine&#44; prednisone&#44; and doxorubicin&#59; CVP&#44; cyclophosphamide&#44; vincristine&#44; and prednisone&#59; IFN-&#945;&#44; interferon alfa&#59; IL&#44; intralesional&#59; IV&#44; intravenous&#59; MZ&#44; mantle-zone&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Type of CBCL&#47;Extension&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">First-Line Treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Alternative Treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Solitary&#47;localized MZ CBCL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Local radiotherapyExcisionAntibiotics<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IFN-&#945; ILRituximab ILCorticosteroides IL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Multifocal MZ CBCL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Watchful waitingLocal radiotherapyChlorambucil<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>Rituximab IVAntibiotics<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IFN-&#945; ILRituximab ILCorticosteroides IL ortopical&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Solitary&#47;localized FC CBCL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Local radiotherapyExcision&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IFN-&#945; ILRituximab IL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Multifocal FC CBCL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Watchful waitingLocal radiotherapyRituximab IV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Chemotherapy&#40;R-CVP&#47;CHOP&#41; inexceptional casesor extracutaneous diseases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Solitary&#47;localized CBCL&#44; leg-type&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">R-CHOP<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>radiotherapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Local radiotherapyRituximab IV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Multifocal CBCL&#44; leg-type&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">R-CHOP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rituximab IV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab182524.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara">In the event of evidence of <span class="elsevierStyleItalic">Borrelia burgdorferi</span> infection&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara">Other appropriate single-agent or combined chemotherapies for low-grade B-cell lymphomas&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Recommendations of the European Organisation for Research and Treatment of Cancer on the Treatment of Cutaneous B-Cell Lymphoma &#40;CBCL&#41;&#46;</p>"
        ]
      ]
      7 => array:7 [
        "identificador" => "tbl0040"
        "etiqueta" => "Table 8"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BCNU&#44; carmustine&#59; CHOP&#44; cyclophosphamide&#44; vincristine&#44; prednisone&#44; and doxorubicin&#59; HDAC&#44; histone deacetylase inhibitors&#59; IFN-&#945;&#44; interferon alfa&#59; MTX&#44; methotrexate&#59; NH<span class="elsevierStyleInf">2</span>&#44; nitrogen mustard&#59; PUVA&#44; psoralen &#43; UV-A&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">First-Line&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Second-Line&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Lymphomatoid papulosis</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Solitary lesion or limited number of lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No treatment &#40;watchful waiting&#41;Topical corticosteroids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Generalized lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MTXNH<span class="elsevierStyleInf">2</span>&#44; BCNU&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PUVAIFN-&#945;Bexarotene&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">CD30</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">&#43;</span></span><span class="elsevierStyleItalic">anaplastic large cell lymphoma</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Solitary lesion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ExcisionRadiotherapyMTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IFN-&#945;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Multiple lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MTXRadiotherapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IFN-&#945;BexaroteneDoxorubicin&#44; CHOP&#44; HDACDenileukin diftitox&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab182518.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Treatment of CD30<span class="elsevierStyleSup">&#43;</span> Cutaneous T-Cell Lymphoma &#40;CTCL&#41;&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:113 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "WHO-EORTC classification for cutaneous lymphomas"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2004-09-3502"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2005"
                        "volumen" => "105"
                        "paginaInicial" => "3768"
                        "paginaFinal" => "3785"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:2 [
                        "titulo" => "WHO classification of tumours of haematopoietic and lymphoid tissues"
                        "serieFecha" => "2008"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The 2008 WHO classification of lymphomas&#58; implications for clinical practice and translational research"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Hematology Am Soc Hematol Educ Program"
                        "fecha" => "2009"
                        "paginaInicial" => "523"
                        "paginaFinal" => "531"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lymphoma incidence patterns in the United States&#58; a population-based study of 3884 cases"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2008-10-184168"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2009"
                        "volumen" => "113"
                        "paginaInicial" => "5064"
                        "paginaFinal" => "5073"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Review of the treatment of mycosis fungoides and Sezary syndrome&#58; a stage-based approach"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Natl Compr Canc Netw"
                        "fecha" => "2008"
                        "volumen" => "6"
                        "paginaInicial" => "436"
                        "paginaFinal" => "442"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update on treatment of cutaneous T-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/CCO.0b013e3283253190"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Oncol"
                        "fecha" => "2009"
                        "volumen" => "21"
                        "paginaInicial" => "131"
                        "paginaFinal" => "137"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of mycosis fungoides with various strengths of fluocinolone acetonide cream"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol"
                        "fecha" => "1968"
                        "volumen" => "97"
                        "paginaInicial" => "165"
                        "paginaFinal" => "172"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical corticosteroids for mycosis fungoides&#46; Experience in 79 patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol"
                        "fecha" => "1998"
                        "volumen" => "134"
                        "paginaInicial" => "949"
                        "paginaFinal" => "954"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Responses of mycosis fungoides to intensive external treatment with nitrogen mustard"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol"
                        "fecha" => "1970"
                        "volumen" => "102"
                        "paginaInicial" => "507"
                        "paginaFinal" => "514"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ointment-based mechlorethamine treatment for mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "1983"
                        "volumen" => "52"
                        "paginaInicial" => "2214"
                        "paginaFinal" => "2219"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical mechlorethamine chemotherapy&#46; Considerations on its use in mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Dermatol"
                        "fecha" => "1984"
                        "volumen" => "23"
                        "paginaInicial" => "180"
                        "paginaFinal" => "186"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mycosis fungoides&#58; management with topical nitrogen mustard"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1987.5.11.1796"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "1987"
                        "volumen" => "5"
                        "paginaInicial" => "1796"
                        "paginaFinal" => "1803"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical mechlorethamine therapy for early stage mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1988"
                        "volumen" => "19"
                        "paginaInicial" => "684"
                        "paginaFinal" => "691"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term effi&#64257;cacy&#44; curative potential&#44; and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1989"
                        "volumen" => "20"
                        "paginaInicial" => "416"
                        "paginaFinal" => "428"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical nitrogen mustard in the management of mycosis fungoides&#58; update of the Stanford experience"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol"
                        "fecha" => "2003"
                        "volumen" => "139"
                        "paginaInicial" => "165"
                        "paginaFinal" => "173"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized&#44; pivotal trial to evaluate the safety and efficacy of 0&#46; 02&#37; Nitrogen Mustard formulations in patients with stage I or IIA mycosis fungoides &#40;abstract&#41;"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:2 [
                        "titulo" => "World Congress of Cutaneous Lymphoma Meeting&#44; Chicago&#44; IL"
                        "serieFecha" => "September 2010"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical carmustine &#40;BCNU&#41; for cutaneous T cell lymphoma&#58; a 15-year experience in 143 patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1990"
                        "volumen" => "22"
                        "paginaInicial" => "802"
                        "paginaFinal" => "810"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical carmustine &#40;BCNU&#41; for patch&#47;plaque mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Dermatol"
                        "fecha" => "1994"
                        "volumen" => "13"
                        "paginaInicial" => "202"
                        "paginaFinal" => "206"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical carmustine &#40;BCNU&#41; in the treatment of mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Ther"
                        "fecha" => "2003"
                        "volumen" => "16"
                        "paginaInicial" => "299"
                        "paginaFinal" => "302"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EORTC consensus recommendations for the treatment of mycosis fungoides&#47;Sezary syndrome"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejca.2006.01.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Cancer"
                        "fecha" => "2006"
                        "volumen" => "42"
                        "paginaInicial" => "1014"
                        "paginaFinal" => "1030"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Fototerapia UVB en la micosis fungoide"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2000"
                        "volumen" => "91"
                        "paginaInicial" => "98"
                        "paginaFinal" => "100"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Narrowband UVB phototherapy for early-stage mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2002"
                        "volumen" => "47"
                        "paginaInicial" => "191"
                        "paginaFinal" => "197"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides&#58; a retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1067/mjd.2003.80"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2003"
                        "volumen" => "48"
                        "paginaInicial" => "215"
                        "paginaFinal" => "219"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Narrowband UVB phototherapy for early-stage mycosis fungoides&#58; evaluation of clinical and histopathological changes"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1468-3083.2006.01635.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2006"
                        "volumen" => "20"
                        "paginaInicial" => "804"
                        "paginaFinal" => "809"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tratamiento con UVB de banda estrecha de los estadios iniciales de la micosis fungoide&#46; Estudio de 23 pacientes"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2007"
                        "volumen" => "98"
                        "paginaInicial" => "259"
                        "paginaFinal" => "264"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of early stages of mycosis fungoides with narrow- band ultraviolet B&#46; A clinical&#44; histological and molecular evaluation of results"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Br J Dermatology"
                        "fecha" => "2009"
                        "volumen" => "218"
                        "paginaInicial" => "1"
                        "paginaFinal" => "6"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1996"
                        "volumen" => "35"
                        "paginaInicial" => "935"
                        "paginaFinal" => "945"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of mycosis fungoides with photochemotherapy &#40;PUVA&#41;&#58; long-term follow-up"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1995"
                        "volumen" => "33"
                        "paginaInicial" => "234"
                        "paginaFinal" => "242"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Photochemotherapy &#40;PUVA&#41; in the pretumour stage of mycosis fungoides&#58; a report from the Scandinavian Mycosis Fungoides Study Group"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Derm Venereol"
                        "fecha" => "1981"
                        "volumen" => "61"
                        "paginaInicial" => "47"
                        "paginaFinal" => "51"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Photochemotherapie bei mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Hautarzt"
                        "fecha" => "1978"
                        "volumen" => "29"
                        "paginaInicial" => "191"
                        "paginaFinal" => "197"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Acta DermVenereol"
                        "fecha" => "1996"
                        "volumen" => "76"
                        "paginaInicial" => "475"
                        "paginaFinal" => "478"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "PUVA treatment of erythrodermic and plaque type mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1981"
                        "volumen" => "4"
                        "paginaInicial" => "423"
                        "paginaFinal" => "429"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques&#46; Long-term follow-up in forty-three patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1985"
                        "volumen" => "13"
                        "paginaInicial" => "613"
                        "paginaFinal" => "622"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Photochemotherapy for mycosis fungoides&#58; long-term follow-up study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Treat Rep"
                        "fecha" => "1979"
                        "volumen" => "63"
                        "paginaInicial" => "669"
                        "paginaFinal" => "673"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phototherapy for cutaneous T-cell lymphoma&#58; online survey and literature review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2008.08.043"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2009"
                        "volumen" => "60"
                        "paginaInicial" => "39"
                        "paginaFinal" => "50"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UVA monotherapy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archderm.141.3.305"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol"
                        "fecha" => "2005"
                        "volumen" => "141"
                        "paginaInicial" => "305"
                        "paginaFinal" => "311"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Joint British Association of Dermatologists and U&#46;K&#46; Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas"
                      "autores" => array:1 [
                        0 => array:3 [ …3]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2003"
                        "volumen" => "149"
                        "paginaInicial" => "1095"
                        "paginaFinal" => "1107"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "UK consensus statement on the use of extracorporeal photophoresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2007.08415.x"
                      "Revista" => array:7 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2008"
                        "volumen" => "158"
                        "paginaInicial" => "659"
                        "paginaFinal" => "678"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Extracorporeal photopheresis in dermatology"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2009"
                        "volumen" => "100"
                        "paginaInicial" => "459"
                        "paginaFinal" => "471"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2010.02.039"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2010"
                        "volumen" => "63"
                        "paginaInicial" => "984"
                        "paginaFinal" => "990"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides&#58; a report of two cases and review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-4632.2008.03177.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Dermatol"
                        "fecha" => "2008"
                        "volumen" => "47"
                        "paginaInicial" => "410"
                        "paginaFinal" => "413"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of the 308-nm excimer laser in the treatment of mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archderm.140.10.1291"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol"
                        "fecha" => "2004"
                        "volumen" => "140"
                        "paginaInicial" => "1291"
                        "paginaFinal" => "1293"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of mycosis fungoides by 308<span class="elsevierStyleHsp" style=""></span>nm excimer laser&#58; a clinical and histological study in 10 patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Dermatol Venereol"
                        "fecha" => "2007"
                        "volumen" => "134"
                        "paginaInicial" => "225"
                        "paginaFinal" => "231"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Radiation therapy in the management of cutaneous T-cell lymphomas"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Treat Rep"
                        "fecha" => "1979"
                        "volumen" => "63"
                        "paginaInicial" => "625"
                        "paginaFinal" => "632"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diagn&#243;stico y tratamiento de los linfomas cut&#225;neos primarios de c&#233;lulas B"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2004"
                        "volumen" => "95"
                        "paginaInicial" => "537"
                        "paginaFinal" => "547"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2008-04-152850"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2008"
                        "volumen" => "112"
                        "paginaInicial" => "1600"
                        "paginaFinal" => "1609"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Radiotherapy for unilesional mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Int J Radiot Oncol Biol Phys"
                        "fecha" => "1998"
                        "volumen" => "42"
                        "paginaInicial" => "361"
                        "paginaFinal" => "364"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Electron-beam therapy for mycosis fungoides&#58; the Stanford University experience"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Treat Rep"
                        "fecha" => "1979"
                        "volumen" => "63"
                        "paginaInicial" => "691"
                        "paginaFinal" => "700"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The management of mycosis fungoides at Stanford-standard and innovative treatment programmes"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Leukemia"
                        "fecha" => "1991"
                        "volumen" => "5"
                        "paginaInicial" => "46"
                        "paginaFinal" => "48"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "1994"
                        "volumen" => "28"
                        "paginaInicial" => "839"
                        "paginaFinal" => "845"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Electron beam treatment for cutaneous T-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Hematol Oncol Clin North Am"
                        "fecha" => "1995"
                        "volumen" => "9"
                        "paginaInicial" => "1057"
                        "paginaFinal" => "1076"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "1999"
                        "volumen" => "43"
                        "paginaInicial" => "951"
                        "paginaFinal" => "958"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Total skin electron radiation in the management of mycosis fungoides&#58; consensus of the European Organization for Research and Treatment of Cancer &#40;EORTC&#41; Cutaneous Lymphoma Project Group"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2002"
                        "volumen" => "47"
                        "paginaInicial" => "364"
                        "paginaFinal" => "370"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Emerging new therapies for cutaneous T-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Clin"
                        "fecha" => "2000"
                        "volumen" => "18"
                        "paginaInicial" => "147"
                        "paginaFinal" => "156"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells&#58; relevance to mechanism of therapeutic action"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Cancer Res"
                        "fecha" => "2002"
                        "volumen" => "8"
                        "paginaInicial" => "1234"
                        "paginaFinal" => "1240"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma&#58; multinational phase II-III trial results"
                      "autores" => array:1 [
                        0 => array:3 [ …3]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.2001.19.9.2456"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2001"
                        "volumen" => "19"
                        "paginaInicial" => "2456"
                        "paginaFinal" => "2471"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Optimizing bexarotene therapy for cutaneous T-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2002"
                        "volumen" => "47"
                        "paginaInicial" => "672"
                        "paginaFinal" => "684"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bexarotene&#58; a clinical review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/14737140.4.2.180"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Anticancer Ther"
                        "fecha" => "2004"
                        "volumen" => "4"
                        "paginaInicial" => "180"
                        "paginaFinal" => "188"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tratamiento de linfomas de c&#233;lulas T con bexaroteno"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermatosifiliogr"
                        "fecha" => "2005"
                        "volumen" => "96"
                        "paginaInicial" => "669"
                        "paginaFinal" => "673"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma&#58;an expert opinion"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2006.07329.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2006"
                        "volumen" => "155"
                        "paginaInicial" => "261"
                        "paginaFinal" => "266"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bexarotene therapy for mycosis fungoides and S&#233;zary syndrome"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Br J Dematol"
                        "fecha" => "2009"
                        "volumen" => "160"
                        "paginaInicial" => "1299"
                        "paginaFinal" => "1307"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interferon in the treatment of cutaneous T-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Ther"
                        "fecha" => "2003"
                        "volumen" => "16"
                        "paginaInicial" => "311"
                        "paginaFinal" => "321"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitetrin versus interferon -2a plus PUVA in patients with cuteneous T-cell lymphoma satges I and II"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "1998"
                        "volumen" => "92"
                        "paginaInicial" => "3578"
                        "paginaFinal" => "3581"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diagn&#243;stico y tratamiento de los linfomas cut&#225;neos de c&#233;lulas T primarios"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2004"
                        "volumen" => "95"
                        "paginaInicial" => "473"
                        "paginaFinal" => "490"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pivotal phase III trial of two doses levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.2001.19.2.376"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2001"
                        "volumen" => "19"
                        "paginaInicial" => "376"
                        "paginaFinal" => "388"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical experience with denileukin diftitox &#40;ONTAK&#41;"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.seminoncol.2010.11.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Oncol"
                        "fecha" => "2006"
                        "volumen" => "33 &#40;Suppl 3&#41;"
                         …3
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Optimizing denileukin diftitox &#40;Ontak&#41; therapy"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2217/14796694.4.4.457"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Novel therapies for cutaneous T-cell lymphomas"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous gamma&#47;delta T-cell lymphoma treated with radiation and denileukin-diftitox"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase 2 study of alemtuzumab &#40;anti-CD52 monoclonal antibody&#41; in patients with advanced mycosis fungoides&#47;S&#233;zary syndrome"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2002-09-2802"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma&#58; a single institution experience from the Robert H&#46; Lurie Comprehensive Cancer Center"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3109/10428190903216770"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2007-03-080010"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            73 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "74"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alemtuzumab in S&#233;zary syndrome&#58; efficient but not innocent"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1684/ejd.2007.0269"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            74 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "75"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Low-dose alemtuzumab is uniquely effective in refractory leukemic cutaneous T cell lymphoma &#40;L-CTCL&#41;&#46; Abstrat 3748"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            75 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "76"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1158/0008-5472.CAN-07-1148"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            76 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "77"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Novel human antibody therapeutics&#58; The age of the Umabs"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/biot.200800110"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            77 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "78"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical efficacy of zanolimumab &#40;HuMax-CD4&#41;&#58; two phase 2 studies in refractory cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2006-12-062877"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            78 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "79"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intralesional therapy with anti-CD20 monoclonal antibody&#44; rituximab in primary cutaneous B-lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            79 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "80"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab&#58; report and follow-up of eight cases"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2006.07523.x"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            80 => array:3 [
              "identificador" => "bib0405"
              "etiqueta" => "81"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Histone deacetylase inhibitors in cancer therapy"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2009.22.1291"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            81 => array:3 [
              "identificador" => "bib0410"
              "etiqueta" => "82"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Histone deacetylase inhibitors as novel anticancer therapeutics"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            82 => array:3 [
              "identificador" => "bib0415"
              "etiqueta" => "83"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vorinostat&#58; a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1517/13543784.16.7.1111"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            83 => array:3 [
              "identificador" => "bib0420"
              "etiqueta" => "84"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase IIB multicenter trial of vorinostat in patients with persistent&#44; progressive&#44; or treatment refractory cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2006.10.2434"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            84 => array:3 [
              "identificador" => "bib0425"
              "etiqueta" => "85"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma&#58; a phase I study&#46; Abstrat 8572&#46; En&#58; 2009 ASCO Annual Meeting"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1990.8.1.27"
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            85 => array:3 [
              "identificador" => "bib0430"
              "etiqueta" => "86"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A novel regimen of vorinostat with interferon gamma for refractory S&#233;zary syndrome"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2008.11.889"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            86 => array:3 [
              "identificador" => "bib0435"
              "etiqueta" => "87"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinically Significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma&#58; final results from a phase 2B&#44; international&#44; multicenter&#44; registration study&#46; Abstract &#35;263"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            87 => array:3 [
              "identificador" => "bib0440"
              "etiqueta" => "88"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinically significant responses achieved with romidepsin in 37 patients with cutaneous T-cell lymphoma with blood involvement&#46; Abstrat 2683"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            88 => array:3 [
              "identificador" => "bib0445"
              "etiqueta" => "89"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2008.21.6150"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            89 => array:3 [
              "identificador" => "bib0450"
              "etiqueta" => "90"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pooled analyses of two international&#44; multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma&#46; Abstrat 8546&#46; En&#58; 2009 ASCO Annual Meeting"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            90 => array:3 [
              "identificador" => "bib0455"
              "etiqueta" => "91"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase II study of oral panobinostat &#40;LBH589&#41;&#44; a potent pan-deacetylase inhibitor&#44; in patients with refractory cutaneous T-cell lymphoma &#40;CTCL&#41;&#46; Abstrat 8555&#46; En&#58; 2008 ASCO Annual Meeting"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            91 => array:3 [
              "identificador" => "bib0460"
              "etiqueta" => "92"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Final results of a phase II trial of belinostat &#40;PXD101&#41; in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma&#46; Abstrat 920"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            92 => array:3 [
              "identificador" => "bib0465"
              "etiqueta" => "93"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2007.11.4207"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            93 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "94"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bortezomib therapy in patients with relapsed or refractory lymphoma&#58; potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2005.04.6789"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            94 => array:3 [
              "identificador" => "bib0475"
              "etiqueta" => "95"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lenalidomide &#40;Revlimid<span class="elsevierStyleSup">&#174;</span>&#41; in patients with cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            95 => array:3 [
              "identificador" => "bib0480"
              "etiqueta" => "96"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current management of primary cutaneous CD30&#43; T-cell lymphoproliferative disorders"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            96 => array:3 [
              "identificador" => "bib0485"
              "etiqueta" => "97"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gemcitabine as frontline treatment for cutaneous T-cell lymphoma&#46; Phase II study of 32 patients"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.21449"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            97 => array:3 [
              "identificador" => "bib0490"
              "etiqueta" => "98"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3816/CLM.2006.n.039"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            98 => array:3 [
              "identificador" => "bib0495"
              "etiqueta" => "99"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gemcitabine treatment in cutaneous T-cell lymphoma&#58; multicentre study of 23 cases"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2009.09230.x"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            99 => array:3 [
              "identificador" => "bib0500"
              "etiqueta" => "100"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S&#233;zary Syndrome"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archderm.144.6.727"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            100 => array:3 [
              "identificador" => "bib0505"
              "etiqueta" => "101"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1600-0609.2008.01197.x"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            101 => array:3 [
              "identificador" => "bib0510"
              "etiqueta" => "102"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pegylated liposomal doxorubicin&#44; bleomycin&#44; vinblastine and dacarbazine &#40;CBVD&#41; in the treatment of advanced primary cutaneous lymphomas&#46; Abstrat 3717"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            102 => array:3 [
              "identificador" => "bib0515"
              "etiqueta" => "103"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term treatment of CTCL with the oral PNP inhibitor&#44; forodesine&#46; En&#58; 2009 ASCO Annual Meeting"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2009.21.8560"
                      "Revista" => array:4 [ …4]
                    ]
                  ]
                ]
              ]
            ]
            103 => array:3 [
              "identificador" => "bib0520"
              "etiqueta" => "104"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pralatrexate is active in cutaneous T-cell lymphoma&#58; results of a multi-center dose-finding trial&#46; Abstract 919"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:3 [ …3]
                    ]
                  ]
                ]
              ]
            ]
            104 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "105"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase II-I-II study of two different doses and schedules of pralatrexate&#44; a high-affinity substrate for the reduced folate carrier&#44; in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2008.20.8470"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
            105 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "106"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Stem cell trasplantation in advanced cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2007.12.021"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            106 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "107"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Trasplante aut&#243;logo de progenitores hematopoy&#233;ticos seguido de bexaroteno oral en paciente con micosis fungoide avanzada"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            107 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "108"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Durable clinical&#44; cytogenetic and molecular remissions alter allogenic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2005.02.774"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            108 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "109"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/sj.bmt.1705968"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            109 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "110"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogenic stem cell transplantation"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [ …5]
                    ]
                  ]
                ]
              ]
            ]
            110 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "111"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S&#233;zary syndrome&#58; a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2010.29.3241"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            111 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "112"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Controversies in the management of the cutaneous T cell lymphomas"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1529-8019.2009.01257.x"
                      "Revista" => array:6 [ …6]
                    ]
                  ]
                ]
              ]
            ]
            112 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "113"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Maintenance therapy in cutaneous T-cell lymphoma&#58; who&#44; when&#44; what&#63;"
                      "autores" => array:1 [ …1]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejca.2007.06.015"
                      "Revista" => array:7 [ …7]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000010300000008/v1_201304241323/S1578219012002727/v1_201304241323/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6170"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Novelties in Dermatology"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010300000008/v1_201304241323/S1578219012002727/v1_201304241323/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002727?idApp=UINPBA000044"
]

Article information

ISSN: 15782190
Original language: English

DOI:10.1016/j.adengl.2012.09.016

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	16	12	28
2024 October	107	43	150
2024 September	88	45	133
2024 August	126	68	194
2024 July	85	30	115
2024 June	95	36	131
2024 May	93	38	131
2024 April	92	24	116
2024 March	69	32	101
2024 February	71	32	103
2024 January	75	48	123
2023 December	71	8	79
2023 November	54	39	93
2023 October	46	39	85
2023 September	52	34	86
2023 August	53	25	78
2023 July	51	48	99
2023 June	49	24	73
2023 May	64	29	93
2023 April	41	22	63
2023 March	40	20	60
2023 February	52	20	72
2023 January	64	35	99
2022 December	51	46	97
2022 November	26	20	46
2022 October	20	29	49
2022 September	21	39	60
2022 August	41	30	71
2022 July	21	38	59
2022 June	27	37	64
2022 May	29	35	64
2022 April	69	50	119
2022 March	73	53	126
2022 February	52	20	72
2022 January	33	46	79
2021 December	61	46	107
2021 November	64	55	119
2021 October	44	60	104
2021 September	33	54	87
2021 August	39	25	64
2021 July	27	37	64
2021 June	31	35	66
2021 May	41	38	79
2021 April	80	54	134
2021 March	51	31	82
2021 February	42	26	68
2021 January	41	18	59
2020 December	35	16	51
2020 November	23	22	45
2020 October	32	16	48
2020 September	64	21	85
2020 August	34	17	51
2020 July	25	16	41
2020 June	42	24	66
2020 May	30	14	44
2020 April	31	19	50
2020 March	39	12	51
2020 February	7	1	8
2020 January	4	1	5
2019 December	8	0	8
2019 November	4	4	8
2019 October	0	4	4
2019 September	8	4	12
2019 August	4	0	4
2019 July	2	8	10
2019 June	6	23	29
2019 May	1	23	24
2019 April	0	17	17
2019 March	2	11	13
2019 February	0	5	5
2019 January	1	0	1
2018 December	4	0	4
2018 October	3	0	3
2018 September	4	0	4
2018 March	1	1	2
2018 February	26	3	29
2018 January	37	8	45
2017 December	41	7	48
2017 November	26	4	30
2017 October	37	5	42
2017 September	45	12	57
2017 August	51	7	58
2017 July	48	6	54
2017 June	69	12	81
2017 May	65	4	69
2017 April	67	14	81
2017 March	47	51	98
2017 February	33	4	37
2017 January	23	9	32
2016 December	48	3	51
2016 November	46	19	65
2016 October	55	23	78
2016 September	52	12	64
2016 August	55	17	72
2016 July	52	11	63
2016 June	11	9	20
2016 May	8	11	19
2016 April	7	13	20
2016 March	9	1	10
2016 February	11	13	24
2016 January	10	11	21
2015 December	10	11	21
2015 November	18	1	19
2015 October	14	23	37
2015 September	13	4	17
2015 August	16	1	17
2015 July	66	5	71
2015 June	64	8	72
2015 May	84	12	96
2015 April	77	13	90
2015 March	71	11	82
2015 February	60	12	72
2015 January	68	28	96
2014 December	36	10	46
2014 November	36	18	54
2014 October	53	27	80
2014 September	7	5	12
2014 August	18	9	27
2014 July	7	10	17
2014 June	25	6	31
2014 May	26	3	29
2014 April	25	2	27
2014 March	20	15	35
2014 February	27	11	38
2014 January	25	7	32
2013 December	31	9	40
2013 November	30	10	40
2013 October	19	10	29
2013 September	16	5	21
2013 August	15	16	31
2013 July	11	16	27
2013 June	6	26	32
2013 May	13	12	25
2013 April	11	24	35
2013 March	20	17	37
2013 February	33	8	41
2013 January	29	4	33
2012 December	24	6	30
2012 November	2	3	5

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter